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A B S T R A C T
This dissertation consists of a review of the literature, past and 
present, pertaining to the metal lithium. An overview is presented 
of its actions, its adverse effects, and its use in medicine particularly 
in psychiatry. As it is not irregular for many patients to receive two 
or more drugs concomitantly and often in a combination which has the 
potential to interact adversely, an overview of these interactions is also 
presented.
Lithium is dramatically effective in controlling manic symptomatology, 
and in reducing the frequency, severity and length of relapses. From the 
double-blind studies reviewed, much evidence has accumulated which does 
support the claim that maintenance lithium not only protects the patient 
from the manic phase of the bipolar illness, but also attenuates future 
bipolar depressions. In some, but not all, cases of primary depression, 
lithium appears to be about as effective as tricyclic anti-depressants. 
Tentative research suggests that some patients in additional diagnostic 
categories may respond favourably to lithium. These are certain "affectve" 
schizoaffectives and aggressive personality disorder, particularly when the 
aggression is coupled to restlessness and mental retardation. When the 
drug has been administered in other disorders ranging from anorexia nervosa 
through personality dysfunctions to sexual disorders, it appears that only 
the affective overlay is influenced by the drug.
LITHIUM A General Overview of its Uses
CHAPTER 1
1.1 Chemistry
The lithium atom has an atomic radius of 1.56 Angstrom units, an atomic
1 1
number of three and a mass number of seven ’ . The atom therefore 
comprises three protons, three electrons and four neutrons spatially 
arranged thus :
Lithium is a monovalent cation. Due to its smaller ionic size, and
1 2
resultant higher polarizing power ‘ , it differs from the alkali metals 
amongst which it is grouped with sodium and potassium, to resemble 
magnesium and calcium - both divalent cations - in much of its 
chemistry .
1.2 Distribution and Prevalence
1 1  1 4
Once identified by Sir Humphry Davey in 1818 ' ’ ‘ lithium's distribu­
tion soon proved to be universal. Its presence in the sun's atmosphere
was established. In the earth's crust, lithium occurs to the extent of 
sixty-five parts per million, thus ranking twenty-seventh amongst elements
occuring naturally in the earth's crust, and in greater abundance than
1 5
tin, lead or zinc * .
Lithium exists in silicate form in some 250 minerals, but only a few are
1 1
mined as commercial ores, such as spodumene ' - the most abundant commer­
cial source of lithium - and as lepidolite and petalite. These occur
in substantial quantities in Africa, particularly in Zimbabwe, where
1 f>
resources at Bikita are estimated at 114.000 metric tons ".
2.
Sizeable deposits of petalite occur also in Brazil, the Soviet Union
and in Namibia (Karibib). Amblygonite is found mainly in Europe,
1 6
Brazil, Namibia and South Africa ' .
Lithium is found also in certain brine deposits, e.g. the Searles Lake 
in California which has been commercially active since 1938. Recently 
the brines of Salor de Atacama in Chile have yielded proof of substan­
tial lithium content and is scheduled to become a new source of lithium 
chemicals. The bulk of the world's lithium reserves is situated in
two areas - the Kings Mountain area in North Carolina and the Black Hills 
1 4  1 5
of South Dakota ' ’ ‘ .
In terms of content, lithium ranks seventeenth among elements naturally
occurring in sea water, with an estimated ratio of 0.1 parts per
million Lithium is present also in mineral waters, in
plants (such as cocoa, tobacco and seaweed) and is normally found in
1 4
human and animal organisms ‘ .
1.3 Non Medical Uses of Lithium
This great availability makes lithium attractively inexpensive, and in 
conjunction with other desirable physical properties (e.g. its high heat 
capacity, the large temperature range of the liquid phase and high 
thermal conductivity, coupled with a low viscosity and density) have 
resulted in the use of lithium as a thickener for lubricating greases. 
These have captured about one-third of the total automobile grease 
market .
Another major industrial use of lithium occurs in ceramics and specifcally
1 4
in the formulation of porcelain enamel ' . As an additive to alkaline 
storage batteries, lithium results in higher output and prolongs life of 
these Edison cells 1'^. A project, still in its infancy, postulates
the use of liquid lithium to generate in a breeder reaction, tritium,
1 6
which is required in thermonuclear fusion power plants ' .
3.
Lithium-perchlorate has been suggested as an oxidizer for solid 
propellant rocket mixtures, while on a smaller scale it has been 
utilized in pyrotechnics for emitting a brilliant red flame when 
heated. This phenomenon - where lithium energy is emitted in the 
form of red light - is fundamental to the determination of its concen­
tration, and forms the basis to flame emission spectrophotometry.
The latter method is obviously simpler and less expensive than the
1 7
atomic absorption method '‘ .
1.4 Historical aspects
In 1817, Johan August Arfvedson working in the laboratory of Baron J.J. 
Berzelius was analyzing some petalite from Swedish iron mines at Utd.
He isolated a sulphate which behaved as an alkali, but reacted atypically 
for sodium, potassium or magnesium. The water-insolubility of the 
carbonate in particular led Arfvedson to the conclusion that he had
discovered the existence of a new alkali element
1.1, 1.4
Its name
is accredited to Berzelius, and derives from the Greek word meaning 
1 4
"stone" * .
After its discovery lithium was isolated the following year by Sir 
Humphry Davey, and remained medically unused for twenty years. However, 
documentation exists that the natural watersprings of Roman Ephesus 
benefited patients suffering from an " i 11 -temperament" .
1 4
Lithium was medically first used in 1841 by Lipowitz ’ for its ability
1 1
to resolve cartilaginous uric acid deposits ' . Enthusiasm for its
1 7
application spread to related rheumatic disorders * . The thermal
cure and use of bottled waters, many presently still marketed, became
1 8
fashionable ' . On the assumption of a uric acid-depression link,
lithium was administered to melancholic patients in 1892 by Alexander 
1 7
Haig ' . Minor claims of lithium as an effective anti-convulsant
1 9
emerged in the early 1900s ’ but appear rather rooted in its hypnotic
effect.
4.
In 1949, lithium surfaced malevolantly, when reports accumulated of
severe poisonings, and some fatalaties as a result of its use as a
salt substitute for patients in congestive cardiac failure and renal
dysfunction During the same year Dr John Cade, an
Australian pschiatrist, and a co-worker Dr Samuel Gershon, in an
attempt to demonstrate a possible excreted toxin in the urine of manic
patients, noted that specimens of urine from these patients injected
intraperitoneally into guinea pigs were more toxic than the control
specimens. The toxin proved to be urea. In order to estimate
the extent to which uric acid increased this toxicity, lithium, as the
most soluble urate was administered. The toxicity to the animals
diminished notably, and lithium viewed serendipitously as having a
protective and quieting effect on the animals Cade, now
encouraged, administered lithium to ten manic patients with excellent
1 4
results, and likewise to himself, noting no discernible ill effects ’ . 
These results published in the Medical Journal of Australia elicited 
hardly any attention. Relatively little was heard of lithium for 
some twenty years, during which time it was probably eclipsed by the 
emergence of the phenothiazine drugs while poor commercial support 
contributed to the general disinterest in this inexpensive mineral.
During this period the awareness of the importance of lithium was kindled
1 10
by the persistence of 5 Gershon and M Schou ' until 1965, when
interest in lithium briskly sprouted, literature accumulated with 
1 11
alacrity * , and the American Food and Drug Administration in 1970
approved its use in mania - again lithium was claimed, medically and 
psychiatrically as a near-panacea.
1.5 Non Psychiatric Medical Uses
Despite its former utilization in gout and related rheumatic disorders,
the present use of lithium in the treatment of cluster headaches is a
"fait accompli" " ' v  * J . Cluster headaches that fail to respond to
other treatment measures may be treated with lithium beginning with 300
milligrammes daily and gradually increasing the,dose to produce a serum
’  1 12
level of one to two mi 11iequivalents per liter (mEq/1) ‘ .
5.
In migraine its use is still wrought with debate
1.14
The granulocytosis produced by lithium has been utilized in the treat­
ment of granulocytopenic states - such as Felty's syndrome, aplastic 
anaemia and acute leukemia .
Analysis of the differential leucocyte response has revealed that the
lithium induced leucocytosis is secondary to a lymphocytopenia and
1.22
accompanied by a neutropenia 
to increase, depending on th(
The bactericidal effect of these neutrophils, however, is diminished,
Neutrophils have been demonstrated
1 23
e serum lithium level, by 620 per cent ' .
24
while the responsiveness of the lymphocytes to antigen is decreased
Lithium has proved successful in the treatment of hyperthyroidism and in
111 1 1 5
malignant states of the thyroid * ’ * . It has been noted that
1 22 1 25
peptic ulcer symptoms diminish with lithium * ’ ‘ . The use of
lithium has also been advocated as effective treatment for inappropriate
1 1 1  1 26
secretion of Antidiuretic hormone ' ’ ' . Success has been claimed
1 27 1 28
in the Kleine-Levin Syndrome ’ , in multiple tics ’ (albeit in a
1 14 1 15 1 29
cyclothymic patient), and in the Gilles de la Tourette syndrome ' ’ ' ’ ‘ . 
However, it is worth noting that ground for belief for the use of lithium 
in these conditions is insubstantial. In other non-psychiatric conditions 
like Huntington's chorea, lithium treatment may be justified on neurobio­
chemical grounds. Experimentally the intracerebral level of gamma-amino­
butyric acid (GABA) increases after lithium administration, and in
Huntington's chorea a chronic striatal GABA deficiency exists. It thus
1 23
appears logical to administer lithium in this condition ‘ . However,
lithium studies in Huntington's chorea are conflicting
The use of the drug has been advocated in the treatment of mitotic states
as ribonucleic acid was noted to diminish in subjects treated with 
' 1 23
lithium ‘ . Lithium has also been utilized to capture certain radio-
1 23
active particles by tumor tissue during radium therapy ' . In Menieres
.. 1.14,1.15 . . . . ... , . 1.23, 1.31
disease , and in hypermagnesemic periodic paralysis
the evidence for the use of lithium remains either anecdotal or conflicting,
therefore requiring additional investigation for substantiation.
6.
CHAPTER 2
2.1 Pharmacokinetics
2.1.1 Absorption
Lithium is readily absorbed when administered orally, subcutaneously,
intramuscularly or intraperitoneally. Only the first route of
administration is used in man, where the bulk of absorption occurs in
2 1
the small intestine, and is completed within six to eight hours ‘ .
Blood levels reach a peak after a single oral dose of lithium citrate
or lithium acetate within one to three hours. It reaches its peak
2 2 .
two to four hours after lithium carbonate ‘ , without disparity among
different age groups. The height of these peaks varies with the dose
of lithium and is not influenced by the type of lithium salt. These
sharp peaks coincide with moderate discomfort in patients: in the form
2 3
of nausea, vomiting, and abdominal pains lasting less than an hour ’ .
However, as the patient adapts to the drug these symptoms usually
2.2
disappear .
It is known that 300 milligram (mg) lithium carbonate raises the serum
2 4
lithium level by 0.25 mil 1i-equivalents per liter (m.Eq./1) ' while
2 5
600 mg would augment this level to 0.3 - 0.6 m.Eq/1 ‘ . It is useful 
to then bear in mind that a negative correlation exists between body 
weight and lithium blood levels, suggesting that heavier Datientsachieve 
lower serum levels .
2.1.2 Distribution
Lithium is not protein bound, and therefore distributes itself throughout
2 4
the total body water space ’ . However, it has an uneven rate of
2 5
tissue penetration * . Transport of lithium into cells is accomplished
2 7 2 8
by diffusion through the sodium channels ' ’ ’ . However, active
2 3
transport across cell membranes has also been described ‘ . Extrusion
from cells is effected - less efficiently than sodium - by the cation 
2 7
pump ' . The rate of uptake of lithium into tissues is rapid in the 
kidney, slower in bone and liver, and slower yet in brain, where high 
concentrations in the pontine region may occur. Elimination of lithium
7.
from the central nervous system (C.N.S.) is equally delayed, and a
serum-to-cerebrospinal fluid (csf) ratio of three-to-one is an established 
2 5
occurrence ‘ . A similar three-to-one ratio exists in serum-to- 
2 5
erythrocytes ' .
2.1.3 Excreti on
Lithium is excreted almost entirely (ninety per cent within forty-eight 
2 5
hours ' ) by the kidneys. The remainder is eliminated in feces (one 
2 9 2 2
to five per cent ' ) perspiration ' , saliva, seminal fluid and milk
in the feeding mother, while a minute amount is relinquished to bone 
2 7
matrix ‘ . Lithium excretion occurs biphasically. A rapid first
2 6 2 9
phase of six to twelve hours ’ * reflects the lithium excreted from
plasma
days.
2.10
A slower second phase follows which lasts ten to fourteen
2 10
This corresponds with lithium removal from the total body space " .
Since lithium is not protein bound it is freely filtered by the glomerular
2 2 2 6
basement membrane ' ’ ' . Of this filtrate seventy to eighty per cent
2 6
is reabsorbed . Mogens Schou originally assumed this process as
2 2
effected by the distal renal tubules ' . This has since been disproved
2 5
by Leslie Baer ' . In the proximal renal tubule, lithium is reabsorbed
2 1
competitively with sodium ' . It is not, unlike sodium, reabsorbed
distally. Because of the competitive proximal reabsorption of the two
ions, a deficiency of sodium, or natri-uresis tends to increase the
retention of lithium. The excretion of lithium is furthermore not
facilitated by diuretics that act at the distal tubules, e.g., thiazides.
Diuretics in fact, result in an increased serum lithium level or in an
2 5
unexpected toxicity despite an unchanged serum lithium level * .
However, aminophyl1ine or osmotic diuresis with urea or mannitol, which 
decrease proximal tubular sodium reabsorption, increase lithium excretion 
The renal lithium clearance is independent of the serum level
2.11
2.5
and
although normally constant at fifteen to thirty ml/min (adult values) 
the renal lithium clearance decreases with age, but also diminishes 
with a lowered sodium intake.
2.2
These observations emphasize the major regulatory rate of sodium in the 
control of renal lithium excretion.
8.
2.2 Pharmacology - The Effect of Lithium on Enzymes
2.2.1 Adenosine - 3' - 5' monophosphate
Urinary levels of Adenosine - 3' - 5' monophosphate (cyclic - AMP, c-AMP)
in humans have been correlated with the clincial status of patients with
2 12
affective disorders. Paul, in 1970 ' , reported low twenty-four hour
urinary c-AMP in depressives, and a high level in manics. A change
towards normal levels of urinary c-AMP resulted in clinical improvement
of both disorders. A decrease of plasma levels of c-AMP in mania has
2 13
been noted during lithium treatment ‘ . However, changes in urinary
2 14
c-AMP related to physical activity have been demonstrated ' . This
suggests that clinical improvement of the sluggish depressive results in
an increase of urinary c-AMP level to normal values. This may imply 
that urinary c-AMP levels reflect a consequence, not a cause of affective 
di sorder.
Several animal studies report a direct effect of lithium on adenylate
cyclase - the c-AMP synthesizing enzyme. Marked inhibition of rabbit
v 2 15
cortex adenylate cyclase was demonstrated by Dousa in 1970 ‘ .
It is postulated that lithium competing with the co-factor - a divalent
cation - magnesium, inactivates adenylate cyclase in many tissues,
2 7
including the brain, kidney and thyroid ’ .
The following illustrates the site of interaction
adenosine tri-phosphate 
(ATP)
Li
adenylate cyclase
Mg ++
(co.factor)
inorganic
phosphate
c-AMP
9.
c-AMP which is involved in the physiology of synaptic transmission '
is required also as a second messenger for hormones to exert their action
2 16
upon their respective target organs ‘ . For example, c-AMP is
implicated in the actions of catecholamines, thyroid stimulating hormone
2 1 6  2 1 7
(TSH), parathyroid hormone, gastrin ' and vasopressin ' . The
inhibitory effect of lithium on thyroid adenylate cyclase is most clinically 
relevant in explaining the hypothyroidism resulting from the treatment of 
lithium, while its inhibitory effect on Anti-diuretic hormone (A.D.H.) in 
the distal renal tubule has polyuria as a direct consequence. Additional 
discussion follows in Chapter 4.
2.2.2 Sodium-Potassium adenosine triphosphatase (Na+-K+ ATPase)
This enzyme is a large lipoprotein, which requires Mg++ as a co-factor to 
hydrolyze ATP to adenosine diphosphate (ADP). Na+- K+- ATPase is involved
in the pump-mechanism of erythrocytes, brain cells, distal renal tubules
, .. .. 2.18 
and many other tissues .
+ 2 13
Investigation have demonstrated a low activity of Na - K+- ATPase in mania '
and a significant negative correlation with the plasma concentration of
2 19
Vanadium - a natural occuring trace element ’ which in fact appears to
inhibit this enzyme. Lithium has been shown to increase the activity of
+ 2 13
Na+- K+- ATPase in patients with affective disorders * . In normals
+ "f 2 7
lithium has no influence on the erythrocyte Na - K - ATPase ‘ . This 
phenomenon has culminated in the hypothesis that a low Na+- K+- ATPase 
activity contributes to the aetiology of mania. However the failure of 
digoxin, which inhibits the activity of Na+- K+ - ATPase ‘ , to influence
the symptomatology of mania, tends to disprove this hypothesis.
2.2.3 Cyclic Guanosine - 3' - 5' monophosphate
Cyclic Guanosine - 3' - 5' monophosphate (c-GMP), the cyclic derivative
of guanosine, is present in tissues in a lesser concentration than c-AMP,
2 16
with which it interacts to produce inhibition in certain systems ' .
c-GMP is coupled to epinephrine activation of alpha-receptors, and the
2 21
enzyme appears to be inhibited by lithium " . Investigations in this
regard are still in its infancy, its implications yet uncertain, and 
require further examination.
10.
2.2.4 Mono-Amine-Oxidase
Mono-Amine-oxidase (MAO) is a convenient way of describing a group of
isoenzymes. It is further sub-classified into M.A.O. type A and 
2 7
M.A.O. type B ' . M.A.O. is found in all tissues which contain 
mitochondria. In the brain high concentrations are found particularly 
in the regions with aminergic neurons where it oxidatively deaminates 
norepinephrine to 3-methoxy - 4 hydroxymandelic acid (VMA), dopamine to
3.4 dihydroxyphenylacetic acid and serotonin to 5 hydroxyindoleacetic
M.A.O. type B occurs in platelets and appears to have a genetically
2 23
determined low activity in patients with bipolar disorder ’ . This
tendency towards a low activity platelet M.A.O. is genetically also
2 7
extended to first degree relatives of the proband * . In the brain,
2 24
M.A.O. level is considered unaffected by lithium ' , while the activity
2 23
of platelet M.A.O. is increased by administration of lithium ' .
2.3 Pharmacology - The Effect of Lithium on Electrolytes and
urine volume;
It is accepted that neuronal and axonal excitability result from the
redistribution of ions across neuronal membranes. It is also assumed
that certain affective disorders might result from these different
electrolyte states. These two theories have led to research into the
electrolyte variations in order to provide understanding about the
neurochemical changes associated with affective disorders, e.g. a raised
intracellular concentration of sodium in depressives, and yet more so in 
2 9
mania ‘ , and a concomitant low intracel1ular concentration of potassium
. , . 2.13
in depressives .
2.3.1 Sodium (Na)
A natri-uresis occurs on the first day of lithium therapy. This
gradually converts to a state of Na - retention by the third day and a
2 5
full return to the normal state by the seventh day ' .
2.3.2 Potassium
A kaluresis occurs on the first day of lithium treatment, and decreases
2 9
during the subsequent two days ' .
2.3.3 Magnesium
Serum magnesium shows a slight increase during lithium treatment
2.24
2.3.4 Calcium
Increased excretion of calcium during lithium therapy has been demonstrated
2 5
in human and animal studies ' .
2.3.5 Urine Volume
The twenty-four hour urine volume rises on the first day of lithium treat- 
2 9
ment ' . The largest diuresis, is correlated with manics who are
2 9
more likely to respond ' . Water retention occurs by the third day
2 5
with a return to the normal state of water balance by the seventh day .
An increase in urine volume has been documented during chronic lithium 
2 5
administration ' . These fluid changes appear independent of
glomerular filtration rate as no significant changes in endogenous
2 '9
creatinine clearance are demonstrated ' . These changes could be
accounted for by the renin-angiotensin-aldosterone mechanism where a
2 13
deficit has been postulated in bipolar patients ' . Although r e m n -
2 5
activity is not decreased by lithium ' , the lithium induced natri-uresis 
and water diuresis stimulate aldosterone excretion via the renin-angiotensin 
system.
From these observations it is clear that lithium alters human electrolyte 
and fluid balance in a characteristic fashion. But research, although 
intensive during the 1960's into these electrolyte variations, has petered 
out to be succeeded by sophisticated techniques concentrated at the 
cellular level.
12.
2.4 Pharmacology - The Effect of Lithium on Some Neuro-Transmitters
2.4.1 Noradenaline (Norepinephrine) (N.A.)
Joseph Schildkraut in 1966, intracisternally administered noradrenaline
(N.A.) into rats. He found that acute lithium administration altered
2 9 2 9
the metabolism of N.A. ’ . This was verified in 1967 by Schanberg ' .
In 1969, J Schildkraut suggested on the basis of his findings that lithium
increased the intraneuronal inactivation of N.A.. Lithium seemed to
decrease the available N.A. required to interact with adrenergic re- 
2 9
ceptors ' . He also demonstrated an increased turnover of N.A. in rat
2 23
brain after lithium administration ' . In a subsequent study
Schildkraut found the disappearance of intracisternally administered N.A.
2 23
to be related to the dose of lithium administered ' . A human study
by Schildkraut, demonstrated an increased urinary excretion of the glycol
metabolite of N.A. - 3' methoxy - 4' hydroxyphenylglycol (MHPG) - durinq
the acute phase of lithium administration. This increased MHPG excretion
2 23
did not persist with prolonged administration of lithium * .
Stern, in 1969, assumed that lithium increased the rate of N.A. disappearance 
2 9
from rat brain * . Corrodi and his associates provided experimental
evidence with rats in 1969, that lithium produced a significant increase
in the turnover of N.A., which was probably due to an increased acitivity
2 1
of noradrenergic neurons ' . Histochemical fluorescent studies suggested
2 9
that lithium affected N.A. depletion in synaptosomes ' . Corrodi also 
demonstrated that prolonged lithium administration resulted in a return to
normal levels of N.A.
2.23
This was verified by Ho and his associates
2.23
The contrary was assumed by Sedvall, and demonstrated by Bliss and Ailion
in 1970. They fed rats for two weeks on a diet containing lithium.
2 23
Their results revealed N.A. levels similar to that of the controls ' .
Subsequent research by Baldessarini and Yorke in 1970 has shown lithium
2 25
to increase synaptosomal uptake of N.A. ' .
Some animal studies have employed electrical stimulation, e.g. research 
done by Katz and Kopin demonstrated that electrical stimulation enhanced 
the spontaneous efflux of N.A. from rat brain. This spontaneous out­
flow of N.A. was not suppressed by the addition of lithium, but the
13.
stimulation-induced release was significantly reduced. A calcium-
lithium link was postulated, when increased calcium concentrations
prevented this lithium induced inhibition of N.A. This suggests
that lithium may interfere with the calcium necessary for the
exocytosis of presynaptic vesicles, thereby diminishing the release
of many neurotransmitters Changes in N.A. turnover appear to
2 23
be dose related, according to Greenspan ' .
Human research into lithium's effect on N.A., centres about the exposure 
of the metabolites of N.A., in either urine or CSF. Haskovec and
Rysanek demonstrated an increased urinary excretion of 3-Methoxy - 
4-Hydroxy-Mandelic acid (V.M.A.) on the first two days of lithium
administration and a decreased excretion of normetanephrine on the fourth
2 23
and fifth days ‘ . Bowers and his associates reported a slight
decrease of homovanillic acid (H.V.A.) in the CSF of four patients during
lithium treatment ^-23^ jn >1972, Wilk reported high MHPG levels in
the CSF of manics. These high levels decreased, with attending clinical
2 23
improvement, during lithium treatment ' .
More recent studies have also demonstrated the significant effects of
prolonged lithium treatment on the noradrenergic system. Linnoila,
in 1983, reported a substantially reduced urinary N.A., normetanephrine,
MHPG and VMA excretion, as well as a decreased whole body N.A. turnover
2 27
after lithium administration * .
2.4.1.1 Conclusion
These reports clearly favour the involvement of lithium with N.A. but 
the data do not as yet lead to a clear picture of the neurobiochemical 
mechanism of the action(s) of this drug.
2.4.2 Serotonin (5-HT)
Earlier research by Corrodi and his associates in 1967 and in 1969 
indicated that lithium has a time related effect. The acute adminis­
tration of lithium neither altered the concentration of 5-HT nor the
turnover of 5-HT. In contrast,prolonged administration of lithium
• • 2 23
resulted in decreased activity of serotonergic neurons ' .
14.
Following acute electrical stimulation of brain slices from lithium-
pretreated rats, Katz in 1968 demonstrated a decrease of spontaneous
2 26
5-HT efflux ' . Prolonged lithium treatment appeared to regionally
stimulate the turnover of serotonin 
2.28
2.9
, possibly by inducing tryptophan
hydroxylase Regional serotonin changes were reported also by
Sheard and Aghajaman who, after demonstrating an increased 5-hydroxy-
indoleacetic acid (5-HIAA) in the rat forebrain, postulated a lithium
induced increase of serotonin metabolism and turnover within the presynaptic 
2 23
neuron ' . These 5-HIAA levels increased in a dose dependant
, , . 2.9
fashion .
Clinical studies have concentrated on the metabolite 5-HIAA found in
human cerebro-spinal fluid. Levels of 5-HIAA in CSF appear to have
increased during successful treatment by Mendels of two manic patients*
2 29
both of whom had low 5-HIAA levels prior to treatment ' . These
2 23
results were duplicated in other studies and challenged by another ' .
Studies on plasma amino acids indirectly postulate that lithium enhances
2 20 . • • • ■ 
the brain serotonin level ‘ . Chronic application of lithium appears
to decrease serotonin receptor binding sites in the hippocampus. This
indicates an enhancement of serotoninergic activity, and is followed by
receptor subsensitivity in this area
2.31
2.4.2.1 Conclusion
These reports indicate that lithium exerts some influence upon the 
serotoninergic system. However, the precise neurobiochemical action 
of the drug on this system remains obscure and open to dispute.
2.4.3 Dopamine
Lithium chloride administered intraperitoneally to rats led Corrodi to 
report that acute administration of lithium did not significantly alter 
the base line level of dopamine 2’23. Prolonged lithium administration 
resulted in a nonsignificant decreased depletion of dopamine 2 '9 . 
Histochemical fluorescent studies indicated some regional differences, 
e.g, an increased depletion of dopamine, was noted in the tubero- 
mfundibular system whereas less depletion of dopamine occurred in the
15.
mesocortical neuronal system
2.9
Chronic lithium administration,
according to Bliss and Ailion in 1970, appeared not to interfere with
2 23 .
levels of dopamine in rat brain ' . Several other investigators
have reported regional dopamine changes 
2 32
of dopamine ’ '
usually an increased level
Clinical trials by Messiha in 1970 reported increased urinary excretion
of dopamine in patients with a manic disorder. This increased dopamine
excretion decreased with successful lithium treatment, while in depressives
2 33
lithium effected no change in the dopamine urinary excretion levels ' .
Bunney, in 1979, suggested that lithium acted by reducing the sensitivity
2 34
of apparent hypersensitive dopaminergic brain receptors ‘ . Research
into this aspect of dopaminergic sensitive transmission is still 
continuing .
2.4.3.1 Conclusion
The results achieved from lithium studies on the dopaminergic system are 
certainly less clear than results obtained from research on either the 
adrenergic or serotonergic systems.
2.4.4 Acetylcholine
Evidence of decreased postsynaptic receptor blockade by lithium was
2 17
produced byWaziri with animal studies ’ . Rat cortical slices were
electrically stimulated by Bowers and Rozitis in 1970 to ascertain the 
base-line efflux of acetylcholine. The procedure was repeated with 
the addition of lithium. The researchers were unable to find signi­
ficant differences between the two studies and therefore concluded that
2 36
lithium did not influence the release of acetylcholine in rat brain ' .
Bjegovic and Randic obtained evidence from cat brain, supporting the
2 37
hypothesis that lithium decreased acetylcholine release ' .
Decreased release and suppressed synthesis of acetylcholine effected by
2 28
lithium were also demonstrated in 1973 by Dawes and Vizi ' .
2.4.4.1 Conclusion
From these reports it is possible to affirm that lithium exerts some, 
albeit obscure, influence on the cholinergic system.
1 6 .
2.4.5 Gamma aminobutyric acid (GABA)
Lithium may also affect the metabolism of amino acids suspected of
being synaptic neurotransmitters in the brain including glutamate
and GABA. In 1971, Gottesfeld demonstrated a slight but significant
2 39
lithium induced increase of GABA in the hypothalamus ' .
2.4.6 Enkephalins
Lithium has been reported to increase striatal enkephalin content apart
2 28
from also modifying the binding ability of opiate receptors ‘ .
Research into the effects of lithium on these neurotransmitters is as 
yet still in its infancy, and reports therefore too scanty to allow 
even a vague deduction.
17.
CHAPTER 3
3.1 PHARMACOLOGY:
3.2 Drug Interactions
It is not irregular for many patients to receive two or more drugs 
concomitantly and often in a combination which has the potential to 
interact adversely. It is thus necessary to appreciate the fact 
that lithium is a drug with many adverse effects and drug interactions, 
whether these drugs be clinically administered or used as abused 
substances.
3.2.1 Alcohol
The combined use of lithium and alcohol causes a decreased excretion of
3 1
lithium, while serum alcohol levels are unaffected by lithium ’ .
A double-blind placebo-controlled study by Judd, demonstrated in twenty-
three 1 ithium-pretreated normal males that alcohol-induced "highs" were
neither attenuated norblocked by lithium. He found however, that
lithium attenuated alcohol-induced cognitive inefficiency, and alcohol
3 2
reversed the subjective aspect of lithium-induced dysphoria ' .
Another double-blind study reported that the combined effects of lithium
and ethanol on reaction time, co-ordination, and attention were antagonistic
3 1
and opposite to those seen when each of these drugs was given alone ' .
In summary it appears that alcohol excesses complicate the management of 
patients taking lithium. This aspect is again discussed in ChapterlO.
3.2.2 Amphetami nes
It has been shown that the amphetamine induced activation may be reduced
3 1
by pretreatment with lithium ' . Lithium has also been reported
3 3
to decrease the amphetamine induced euphoria ’ .
18.
3.2.3 Anaesthetic agents
The action of both the non-depolarizing and depolarizing neuromuscular
blocking agents, appear to be prolonged in some lithium treated 
3 4
patients ‘ . This may be explained by the possibility of a genetic
variant of the alleles at locus of chromosome I which govern the
biosynthesis of cholinesterase. Atypical homozygous alleles would
result in a suxamethonium sensitive individual. Psychiatric patients,
according to Whitaker, showed a greater tendency to possess a rarer form
3 5
of this genetic variant than a standardized control group ‘ .
3.2.4 Antibiotics
A single case report exists of tetracycline increasing serum lithium
3 1
level - possibly secondary to the nephro-toxic effect of the antibiotic ' 
Current clinical experience however suggests a general compatibility.
A report of spectinomycin increasing the serum lithium level of a patient
3 6
on maintenance lithium treatment has also been documented ' .
3.2.5 Antidepressants
3.2.5.1 Tricyclics and Tetracyclics
Lithium is considered to be quite compatible with antidepressants
3.7
A potentiating effect by lithium on tricyclics has been demonstrated by
3 8
Lingjaerde in a controlled, double-blind study * . This assumed
synergistic action of lithium has been reported also by Birkhimer in
3 9 3 10
relation to trazodone ‘ , by de Montigny in relation to amitriptyline ’
and by Heninger in a placebo-controlled, double-blind study in relation
3 1 1
to amitriptyline, mianserin and desipramine * .
3 12
Several reports to the contrary have surfaced from other researchers ’ 
while a recent report from Prien has demonstrated the 1ithium-imipramine 
combination to have no advantage over imipramine in a long-term double- 
bl ind study
19.
Certain adverse reactions associated with the combined use of lithium 
and antidepressants have been documented. The most common being an 
intensified lithium-induced tremor, the emergence of extrapyramidal
symptoms, an additive antihyroid effect and the precipitation of
. 3.12
seizures .
3.2.5.2 Monoamine Oxidaze Inhibitors (MAOI)
3.12
3 14
Assumptions abound that lithium is compatible with the MAOI's ' .
Reports have been documented that the MAOI's may synergize with lithium
Research has also indicated that certain refractory depressive states
3 15
may respond favourably to the lithium-MAOI combination ‘ . An adverse
reaction associated with this combination appears to be the possibility
of the development of tardive dyskinesia. The appearance of tardive
dyskinesia in two subjects treated with lithium-MAOI combination was
reported by Stancer in 1979. He suggested that prolonged administration
of this combination resulted in dopamine receptor hyperactivity
Beitman suggested that lithium accelerated the re-uptake of dopamine by
3 17
synaptosomes, thereby reducing the total amount of dopamine ' .
This neuroleptic-like activity of lithium might explain the short-term 
amelioration of tardive dyskinesia by lithium as well as the appearance 
of dyskinetic movements later in lithium therapy.
3.2.6 Anticonvulsants
3.2.6.1 Carbamazepi ne
A possible synergistic effect between lithium and carbamazepine has been 
3.1 , 3.18
establi shed 
resistant bipolar disorder
and this combination may be effective in lithium
3.19, 3.20 TU , . . . . . .
. The carbamazepine-11 thi urn
combination was initially also thought to combat lithium-induced polyuria
3 1
but this hypothesis has been refuted ' .
3.21
Although these two drugs are assumed to be compatible, severe possible
neurotoxicity has been reported where plasma levels of both drugs remained
3 22
within normal limits ' . These adverse interactions between lithium
and carbamazepine however have been poorly substained. This aspect is 
amplified in Chapter 5.
20.
A possible synergistic effect between lithium and phenytoin has been
demonstrated in humans. The synergism resulted in an increased
3 23
lithium level ' . Animal studies have produced conflicting results
3 1
with the use of this drug combination ' . However, studies are few
and unsubstantiated.
3.2.6.2 Phenytoin
3,2.7 Antihypertensive agents
3.2.7.1 Methyldopa
A few reports of neurotoxic symptoms occurring with this combination
3 6
and with a therapeutic lithium level have been documented ‘ . These 
reports however, obviously do not allow generalizations.
3.2.7.2 Propranolol
No adverse interactions between lithium and propranolol have been
documented. This drug combination has been used often in the treatment
3 24 3 25
of lithium-induced tremors * ’ ’ . In a study of ten subjects with
lithium-induced tremors, Kirk found propranolol to alleviate but not
3 24
extirpate the troublesome symptom ' . This may be due to propranolol
merely improving the superadded tremor of anxiety in 1 ithium- induced
+ 3.26
tremor .
3.2.7.3 Reserpi ne
Mild adverse effects with the combination 1ithium-reserpine have been
3 27
reported in a small uncontrolled study ' . This combination has
also proved more effective than lithium or neuroleptics alone in the 
treatment of certain intractable affective disorders. On the basis of
this finding the authors postulated a synergistic action between these
. 3.28 ~
drugs .
3.2.8 Anti rheumatics
Animal studies have indicated that indomethacin and phenylbutazone
3 1
reduce the renal lithium clearance ' . These two drugs have 
similar effects in humans, with the added disadvantage of increasing the 
tubular reabsorption of lithium. This results in an increased serum 
lithium concentration often to the point of intoxication.
Indomethacin has been reported to increase the serum lithium level by
thirty to fifty-nine per cent within seven days in seven patients.
The subjects had a steady state plasma lithium level when indomethacin
3 29
was added in a dosage of fifty milligrams three times daily ’ .
3 30
Similar findings were reported by Reimann ' who assumed the reduced 
renal lithium clearance level to originate from the suppression of renal 
prostaglandin E2 .
A doubling of lithium level was achieved by phenylbutazone, but this
3 6
still requires substantiation * . The same applies to ibuprofen where
3 31
a possible increase of serum lithium level is postulated ' .
3.2.9 Barbi turates
Although certain results have been forthcoming from animal studies, no
adverse or beneficial interactions have been reported in human subjects
3 1
with a 1 ithium-barbiturate combination ‘ .
3.2.10 Benzodiazepines
A single well documented case report of hypothermia from the combination
3 32
diazepam - lithium has been described ' . This reaction might
suggest an idiosyncratic phenomenon, as the combination has been widely 
used clinically without ill effect.
3.2.11 Pi goxi n
Both digoxin and lithium may cause bradyarrhythmias. The effects of this
digoxin-1 ithium combination have been documentated from animal studies,
3 16
while a human study reported the occurrence of bradyarrhythmias * .
22.
Substantiation of the adverse effects of this combination is still 
requi red.
3.2.12 Pisulfi ram
No adverse interaction between disulfiram and lithium has as yet been 
reported.
3.2.13 Pi ureti cs
3.2.13.1 Carbonic Anhydrase . Inhibitors
Acetolamide
Animal and human studies demonstrated that single doses of acetolamide
3.1, 3.33
increased the excretion of lithium 
to the use of the diuretic in the treatment of lithium intoxication
These results have led
3.7
3.2.13.2 Loop Piuretics
Furosemi de
Reports on the combination 1ithium-furosemide are conflicting, and
cases of increased lithium excretion but also of lithium retention with
3 1
resultant toxicity have been described ‘ . Saffer and Coppen
concluded that the drug was without ill effects in patients treated with 
3.34
lithium .
3.2.13.3 Pista 1 Tubule Piuretics
Thiazides
Lithium interaction with thiazides is well documented. Thiazides
cause decreased renal lithium clearance with a corresponding increase 
in serum lithium level to the point of intoxication
The combined use of thiazides and lithium is therefore contra-indicated.
By decreasing urine volume, thiazides have proved effective in lithium-
3 1
induced diabetes insipidus ' .
23.
3.2.13.4 Osmotic Diuretics
(1) Mannitol
Animal studies indicate a significant increase in lithium excretion
3 36
Similar results have been obtained in human studies ' .
3.1
(2) Urea
The administration of urea decreases the serum lithium level, and an 
infusion of urea with sodium lactate may raise the excretion of lithium 
by 100 - 200 per cent 3 '37.
The use of both urea and mannitol for osmotic diuresis has been advocated 
in the treatment of lithium intoxication.
3.2.13.5 Potassium - Sparing Diuretics
Spi ronolactone
A nonsignificant increase in lithium excretion occurs after a
of spironolactone, while with prolonged administration of the
3 1
the serum lithium level tends to rise ‘ .
single dose 
diuretic
3.2.13.6 Xanthine Diuretics
Aminophylline, Theophyl1ine
Administration of a single dose of aminophyl1ine causes a decreased serum
3 33 3 35
lithium level by decreasing proximal tubular sodium reabsorption ' ’ "
Its use therefore;has been advocated in the treatment of lithium intoxica­
tion and will be discussed in Chapter 4.
3.2.14 Iodide compounds
Short-term administration of excess iodine to man inhibits thyroid hormone 
synthesis - the Wolf-Chaikoff effect. This effect occurs particularly
3
in patients who already have an abnormality in thyroid hormone synthesis *
38
24.
Lithium carbonate accumulates in the thyroid gland against a concen­
tration gradient, and like iodine is capable of blocking thyroidal
3 37
release of tri-iodothyronine (T ) and thyroxine (T^) ' . The
summation of these effects would lead to synergism of the drugs when 
administered concurrently. This has indeed been demonstrated by
A further
3 39 3 37
Jorgensen ' and documented by Shopsin in 1973 ’ ,
discussion of the effect of lithium on thyroidal hormones follows in 
Chapter 9.
3.2.15 Levodopa
In humans, adverse interactions between lithium and levodopa have not 
been demonstrated. In fact lithium may have some value in treating
certain side effects of levodopa
3.40
It has been suggested that
lithium and L-dopa interact because each affects norepinephrine 
3 4
metabolism ' . Another possibility is that L-dopa induces beha­
vioural changes by dopaminergic mechanism, and that lithium acts at a
3 42
different but functionally related brain site * .
3.2.16 L-Tryptophan
There is no evidence from human studies, of an adverse interaction
between lithium and Tryptophan. Chouinard reported a lithium-
refractory manic patient, who improved with the addition of L-tryptophan
A study by Brewerton indicated that the lithium-tryptophan combination
3 44
acted synergistically, particularly in schizoaffective patients * .
In depressive states the combination has been reported superior to 
3 45
tryptophan alone ' . Several other researchers have suggested a
3.43
beneficial effect from this combination in the treatment of depression
3.1
3.2.17 Marijuana and Cocaine
Lithium has not been shown to interact adversely with either marijuana 
. 3.1
or cocaine
25.
3.2.18 Neuroleptics
3.2.18.1 Chlorpromazine
Chlorpromazine (CPZ) stimulates lithium excretion, thus decreasing the
3 46
serum lithium level while lithium itself may decrease CPZ levels * .
Reports of neurotoxicity as an adverse effect from this combination
3 47 3 48
have been documented ’ ’ ’ , but in view of the fact that lithium
and CPZ in combination have been administered to many patients without 
similar results, the combination may be cautiously regarded as safe.
3.2.18.2 FIuphenazi ne
The combiantion lithium-fluphenazine appears to be compatible in the
vast majority of cases, although some reports of neurotoxic reactions 
3 49
were issued ’ .
3.2.18.3 Haloperidol
Animal studies have shown lithium not to alter brain levels of haloperi­
dol but to block haloperidol induced dopamine receptor hypersensitivity
A fatal neurotoxic effect has been demonstrated, where a critical factor
appeared to be the order of drug administration. This has also applied
3 1
to CPZ and flurazepam ' .
3.50
3.2.18.3.1 Toxic Neurological Reaction
The alarming possibility of a toxic neurological reaction in humans 
following the combined use of haloperidol and lithium was raised by
3 51
W J Cohen and N H Cohen at the Tenth International Congress of Neurology '
Their report on four patients was subsequently published in 1974, and
3 52
recorded widespread publicity ' . This report indicated two patients
to have suffered widespread irreversible brain damage, while the remaining 
two were afflicted with persistent dyskinesias. All four patients 
showed extrapyramidal syndromes and all four developed cerebellar signs.
The authors assumed haloperidol to have interacted with lithium producing 
a synergistic effect, resulting in an "extreme alteration of cell membrane 
function" with some nerve cell destruction.
26.
Intensive scrutiny and review of this report has produced some
3 53
criticism tnereof ' .
(a) One patient manifested tardive dyskinesia before treatment.
(b) Drug contamination was present in three patients, i.e. 
Benztropine which may itself induce neurotoxicity and 
toxic psychosis.
(c) The manic-depressive diagnosis was questioned.
(d) The possibility of an infectious aetiology became of 
practical importance.
Further reports, which partially confirmed the findings of neurotoxicity 
at a therapeutic level of lithium were published. Marhold reported
reversible neuromuscular symptoms, after treating two oligophrenics and
3 54 •
one manic patient ' . Loudon and Waring reported on seven patients
with bipolar disorder, manic phase, who developed signs of reversible
neurotoxicity including reversible but prolonged extrapyramidal side
effects
3.55
In a retrospective study of 425 patients on this
combination, Baastrup and Schou showed no patient to have developed a
3 56
syndrome resembling that described by Cohen and Cohen ' . Fetzer,
in 1981 reported on one case of reversible encephalopathy due to a
3 57
1ithium-haloperidol combination ' . Thomas and his associates
3 58
made a similar inference in 1982 ' . Amdisen questioned the validity
of standardized sampling for monitoring lithium serum concentrations and
assumed the adverse interaction to simply reflect "pure lithium
3 59
intoxication" ’ . Mann stated that although lithium may cause
parkinsonian symptoms through its antidopaminergic effect, there was no 
evidence of lithium producing tardive dyskinesia. He reported a
single case in which the co-administration of haloperidol, within seven
3 60
days, resulted in a dyskinetic syndrome * . Keitner presented a single
case of reversible neurotoxicity precipitated by the 1 ithium-haloperidol
.. 3.61
combination .
Despite these adverse reports, this combination has been widely and 
beneficially administered without incident to many thousands of patients.
27.
One might thus speculate on the vunerability of certa 
to develop this syndrome, and display caution in its 
by diminishing the dosage of both drugs when jointly
in individuals 
usage - possibly 
administered
3.2.18.3.2 Neuroleptic Malignant Syndrome
Spring, in 1981 described a case of combined lithium and haloperidol 
toxicity characterized by hyperpyrexia, severe rigidity, mutism and the
He postulated thatdevelopment of irreversible tardive dyskinesia.
3 52
the four subjects documented by Cohen ' suffered similar encephalo-
3 63
pathies ' . It is interesting that these cases due to high-dose
haloperidol with lithium are now generally regarded as Neuroleptic
3 64
Malignant Syndrome (NMS) . The aetiology of NMS is unknown.
Lithium may have a selective dopamine blocking action that probably
3 64
enhances the extrapyramidal effect of haloperidol ’ . Small dosages
of the latter are thus less likely to result in significant neurotoxic 
effects. Although anticholinergics have been advocated, no specific
treatment is available for NMS. Discontinuation of the drug combination
3 63
seems not to alter the course of the syndrome * .
3.2.18.4 Thi oridazi ne
Patients treated with the combination lithium-thioridazine have been
observed to develop oedema, which was consistently removed by spironolactone 
3 65
administration ' . A more serious adverse effect is a reversible
neurotoxic syndrome characterized by delirium, and an abnormal electro-
3 66
encephalograph but without extrapyramidal features * . Two different
types of neurotoxic reactions are thus postulated :
( i ) a malignant extrapyramidal syndrome with lithium and haloperidol.
(ii) an exclusive neurotoxic syndrome without extrapyramidal features,
3 63
seen in the lithium-thioridazine combination ’ .
3.2.18.4.1 Conclusion
Although lithium generally seems compatible with thioridazine, and while 
this combination has been used safely and beneficially, it is yet wise to 
keep patients treated with this combination under close observation.
28.
Any marked loss of sodium, caused by intercurrent pyrexia or a low-salt
diet, produces a negative sodium balance with resultant lithium retention
3 67
to the point of intoxication ' . Excessive moisture loss during
strenuous exercise or exposure to temperate climates have similar results 
To provide adequate sodium chloride retention it may be advisable to
prescribe 1 000 to 4 000 milligrams of sodium chloride daily for these
3 68
patients ' . The severity of lithium toxicity may be reduced also
by the administration of sodium, ^-68, 3.69^
3.2.19 Sodium
3.2.20 Sodium bicarbonate
The renal excretion of lithium is stimulated by the urinary alkalinizing
3 33
effect of sodium bicarbonate ' . Sodium bicarbonate has been suggested
3 70
as treatment for lithium intoxication ' .
3.2.21 Steroids
Steroids appear to decrease the serum lithium concentration by increasing
3 71
renal lithium excretion ' .
3.2.22 Thyroid drugs
Lithium is assumed to enhance the effect of drugs that suppress thyroid
function, and has successfully been administered in this combination for
3 72
the treatment of thyrotoxicosis ‘ . This aspect is discussed in
Chapter 4.
3.3 Lithium and the Electrocardiograph (ECG)
Transient ECG changes are observed in twenty per cent of lithium treated
3 73 3 74
patients, who are without clinical signs of lithium intoxication ' ’ ' ,
Within five days of administration lithium induces T wave changes which
remain stable and disappear within three to five days after discontinuation 
3 75
of the drug ' . These changes are similar to changes induced by
imipramine-type drugs and by hypokalaemia, thus suggesting intracellular
29.
modifications of potassium
3.37
The T wave changes consisted 
3 75
of T wave flattening or inversion ' . Occasionally a QRS complex
3 62
widening is noted ' . Lithium was administered to patients who
had EEG abnormalities prior to treatment and in none of the patients
did the drug aggravate any of these EEG changes, nor was there any
clinical aggravation of pre-existing cardiac disease. Schou thus
3 75
assumed these changes to be relatively benign * . In lithium
intoxication an added reversible change of ST segment depression was
3 76
noted ' . Reports of reversible sinus node dysfunction, usually
occuring in the elderly at a therapeutic lithium level, have been 
documented .
3.3.1 Conclusion
Considering these problems it is necessary to proceed cautiously with 
lithium in the treatment of the elderly and of patients with cardiac 
dysfunction.
3.4 Lithium and the Electroencephalograph (EEG)
Acute lithium administration is assumed to produce no significant EEG
changes, while prolonged lithium therapy has resulted in changes in
3 76 i
seventy per cent of patients ' . The lowest serum lithium level
for the initial EEG changes to develop appears to be in the region of
0.7 m Eq/1. Initially a slowing of the dominant alpha rhythm and
increases in amplitude occur. Thereafter beta-activity increases
with alpha rhythm diminishing. Previous focal abnormalities are
accentuated, and previously absent focal abnormalities may be unmasked
As a state of toxicity is reached, theta and delta activity appear, with
3 7
the latter becoming paroxysmal and located more frontally ' . The
occurrence of neurotoxicity corresponds not to the serum lithium level
3 79
but to the presence and severity of EEG changes ’ .
3.78
30.
Several reports have been published detailing lithium induced 
seizures . It is paradoxical that lithium,
formerly used as an anticonvulsant, is capable of precipitating 
seizures during treatment or withdrawal from lithium treatment. 
This aspect is discussed in Chapter 4. Sleep EEG studies have
indicated that lithium does not influence total sleep time but
. . . . 3 81
suppresses rapid eye-movement stages .
3.5 Lithium and Electroconvulsive Therapy (ECT)
Although lithium and ECT have similar effects on urinary excretion
of norepinephrine metabolites, e.g., decreased urinary norepinephrine
3 8 ?  3 1 4
normetanephrine, MHPG and VMA - -- , and are considered compatible ' .
there are indications that combined treatment with lithium and ECT
is less effective than ECT alone. Indications are that lithium may
prolong apnoea by potentiating neuromuscular blocking agents
while Small suggests that lithium and ECT should not be used simultaneously,
and that lithium treatment should be delayed until it is certain that ECT
would not be required
31.
CHAPTER 4
4.1 Pharmacology
4.2 Toxicology of Lithium
Lithium treatment is often associated with side effects. These are 
summarized in Table 4.1.
Because the more frequently observed side effects are transient, and 
while certain toxic reactions are manifestations of prolonged lithium 
therapy, it may be convenient to classify this formidable list of sequelae.
4.3 Classification
(i) Mi nor/Transient/Typical early effects
(ii) Minor to Moderate persisting effects
(iii) Complications resulting 
treatment and unrelated
from prolonged lithium 
to dosage
(iv) Lithium intoxication
The initial lithium induced side effects are common, albeit mild, and
4 1
occur at therapeutic serum lithium levels ‘ . These side effects
coincide with the absorptive peaking of serum lithium concentration,
but are correlated rather with the steepness of the rise than the height 
4 2
of the peak ' . To avoid these extreme flings of blood lithium 
levels, thus reducing the incidence of side effects, sustained action 
lithium preparations have been introduced.
32.
TABLE A.l
Tye adverse effects of lithiurr. therepy ere protean aria diverse.
• ese are summarized, without ar. obligatory secuence c' occurrence to serve as a checklist
A
CARDIOVASCULAR SYMPTOMS
b
central nervous system
EFFECTS
C
DERMATOLOGIC
EFFECTS
D
GASTRO INTESTINAL 
SYMPTOMS
1. ECG charges 1. EEG changes I .  Nor-specif ic i Nausea
2. Various arytrmias 2 . Seizures dermatitic lesiors 2. Abdominal pains
3. Hypotension 3- Anaesthesia of skin 2 . Induction of 3. Vomiting
1 . Peripheral circulatory A. Vertigo psoriasis A. Flatulence
failure cJ  • Slurred speech 3. F o l l ic u l i t is  and 5- Diarrhoea
3. Circulatory collapse £. Blurring of vision alopecia 6. Metallic taste
7. Urinary and faecal ?. T hi rst
incontenence 8. Sialorrnoea
8. Neurotoxic manifests- 9. Salivary Gland
tions enlargement
9. Neuroleptic malignant 10. Constipation
syndrome 11. Anorexia
E F 
HAEMAT0L0GIC EFFECTS MENTAL SYMPTOMS
G
METABOLIC AND
END0CRIN0L0GIC
SYMPTOMS
H
NEUROMUSCULAR
SYMPTOMS
Leucocytosis - 1. Inconcentration i .  Weight loss 1. General muscular
2. Lethargy 2. Weight gain weakness
iu Neutrophilia 3. Slow mentation 3. Thyroid symptoms: 2. Tremor
i i )  Lymphocytopenia A. Somnolence i .  transitory bio- 3. Ataxia
5. Restlessness chemical changes A. Muscle hyper-
6. Change in libido without c lin ica l i r r i t a b i l i t y
7. Stupor signs or symptoms i .  fasciculatior
8. Withdrawal symptoms i i .  myxoedematous i i .  clonic movements
9. Coma goitre 5. Choreoatheiotic
i i i .  euthyroid goitre movements
iv . hyperthyroidism 6. Hyperactive deer
v. exophthalmus tendon reflexes
A. Effects on the 
Parathyroid 
3. Ef fects or clood 
glucose
'7. Parkinsonism
6. Effects cn tne 
adrenal cortex
7. Effect on growth 
hormone
8. Effect on prolactin
I J K 
OSSEOUS EJECTS QUINCKE'S OEDEMA RENAL EFFECTS
L
TERATOGENIC ERr[CTS
r
Autoimmune Arte r it is  i .  Polyuro-polydipsic
svndrome
2. Various nephropathies
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4.4 Typical Early Reactions
The initial side effects are represented by inconvenient toxic
reactions, which are usually transient and to which the patients
4 1
readily acclimatize themselves ' .
4.4.1 Gastro-intestinal Symptoms
These consist of flatulence, nausea and sometimes emesis. Transient
abdominal discomfort lasting a week is found in one-third of lithium 
4 3
treated patients ' . Troublesome diarrhoea occurs in twenty per
4 4 4 5
cent of patients ‘ . This is successfully treated with diphenoxylate ’ ,
4 4
A sensation of thirst is reported in seventy per cent of patients ’ .
Lithium excreted by the salivary glands accounts for the metallic taste
4 2 '
experienced by many patients * .
4. 4.2 Central Nervous System (CNS) Symptoms
Another typical side effect that routinely occurs early in lithium
4 2
treatment is a fine ten cycles per second tremor of the hands * .
4.6
toThis occurs with normal lithium levels in twenty-six per cent
4 4
forty-five per cent ‘ of patients, but represents a handicap in
only ten per cent. The tremor is worsened by fatigue and emotions,
4 6
neuroleptics, antidepressants, and excessive caffeine intake ’ .
It does not yield to anticholinergics or antiparkinsonian medication,
4 2 4 5
but is often responsive to a beta-blocking agent, e.a. propranolol ’ ’ ’ .
* 4 2
Transient sensations of muscular weakness also occur early in treatment * .
Should these symptoms persist, a temporary reduction of dosage or changing
4 7
to another lithium preparation may be helpful ’ .
4. 5 Mild to Moderate Tardive Effects
These sequelae generally appear after a short time-lag and tend to persist.
Although muscular weakness has generally disappeared at this stage of
4 3
treatment, a tremor may persist in four per cent of patients ‘ , and
4 2
may often be accompanied by fasciculation ’ . Mental symptoms
4 2
surface as a subjective experience of indifference and slight malaise .
34.
4.6 Complications of Prolonged Lithium Treatment
4.6.1 Cardiac Effects
Twenty to thirty per cent of lithium-treated patients show reversible
. . 4 3 4 8
EC6 changes consisting of T wave flattening or inversion ' ’ ' .
The elderly, and patients with pre-existing cardiac pathology, are
4 9 4 10
especially prone to lithium induced cardiac conduction disorders ' ’ ‘
Other lithium induced cardiac side effects occur infrequently, eg.,
4 11 ■
myocarditis or sudden death ‘ . This can be readily explained on the
basis of partial substitution of lithium for potassium, or of a lithium
induced inhibition of adenylate cyclase, thus inhibiting cholinergic
mechanisms with a resultant poor effect of norepinephrine on the 
4 3
myocardium ' .
4.6.2 Central Nervous System Effects
4 8
Lithium induced EEG changes are common ' , yet there is some debate as
4 12
to whether lithium increases or decreases the frequency of seizures ‘ .
However, in temporal lobe epilepsy the common denominator appears to be
4 3 4 12 4 13
a deterioration of the disorder Kindled seizures are
4.14
unaffected by lithium The mode of action of the lithium ion on
the "epileptic neuron" is still obscure. It may be situated at the
4 1 2  4 1 5
level of neuronal calcium, magnesium, noradrenaline ' or GABA ' ,
Other CNS symptoms such as lethargy, slurred speech, blurred vision,
confusion, ataxia and nystagmus are usually seen at higher lithium levels
although they may occur with levels well within the therapeutic range -
4 3
and represent a prodrome associated with impending intoxication ' .
4.6.3 Dermatologic Effects
These side effects are thought to be a rare occurence with an overall
incidence of one to three per cent, although Sarantidis has reported an
4 16
occurrence as high as thirty-four per cent * . Women especially,
are susceptible to these manifestations, which tend to develop within
• 4 6
one year of initiation of lithium treatment ‘ .
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4.6.3.1 Cutaneous Reactions
A variety of non-specific cutaneous reactions have been reported,
but the common denominator seems to be an aggravation of pre-existing
4 2 4 8
lesions. These reactions include acne ‘ ’ ' , transient maculo-
4 3 4 1 6  4 8
papular rash ' ’ ’ and exfoliative dermatitis ‘ . A case of
lithium induced lichen simplex, without re-emergence after lithium
4 17
reinstitution has been reported ‘ . Other lithium induced dermatologic
side effects are general pruritic reactions, stomatitis, and angular 
4 16
chelitis ' . Most of these sporadic reactions respond well to
antihistamines or topical steroids, and disappear with lithium discon­
tinuation, often not to re-emerge with lithium reinstitution.
The induction or exacerbation of psoriasis by lithium has been reported
more often - and especially in patients with pre-existing psoriasis and
in subjects who claim a positive family history of the disorder - than
4 6
any other dermatologic effect ' . It is resistant to common therapy
4 3  4 1 8  4 1 9
and usually requires discontinuation of lithium The
mechanism whereby lithium influences psoriatic skin (where low levels of
c-AMP have been demonstrated) is postulated at the level of adenylate
cyclase. This enzyme is inhibited by lithium resulting in further
4 18
reduction of c-AMP ‘ , thus exacerbating the psoriatic condition.
4.6.3.2 Lithium's Effect on Hair
4 16
Folliculitis, as a lithium induced side effect has been documented ' .
Lithium accumulates in the hair causing alopecia. Hair may regrow if 
the drug is discontinued . Since alopecia may be a
manifestation also of lithium induced hypothyroidism, and therefore readily 
corrected with exogenous thyroid, evaluation of thyroid function becomes 
necessary when patients present with this complaint.
4.6.4 Gastro-intestinal Symptoms
Apart from the transient sequelae experienced at the onset of lithium
treatment, infrequent moderate symptoms have been reported, e.g.,
4 22
salivary gland enlargement ' and a possible lithium induced intestinal
,... 4.23
vasculitis .
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4.6.5 Haematologic Effects
In a majority of patients, lithium produces a reversible, often
intermittent 1eucocytosis, without the shift to the left seen in
4 2 4 3  4 8  4 24
infective processes ’ '’ . This elevation is not
4.7
dependent on the dose or the serum lithium concentration •
Analysis of the differential leucocyte response has revealed that
the lithium-induced leucocytosis is secondary to neutrophilia and
4 2 4 3
accompanied by a lymphocytopenia ’ ’ ’ . The mechanism whereby
lithium induces these changes is yet unclear but may involve inhibition
4 25 4 26
of the thymus-dependent lymphocyte suppressor cells * ’ ‘ . These
side effects are generally considered benign and do not require discon­
tinuation of lithium therapy.
4.6.6 Mental Symptoms
These symptoms include inconcentration and imparied memory and may,
4 27
therefore, have some importance as regards the school-going adolescent
Improved, recall for difficult material has been shown by Kusumo in
4 ?P. 4 29
1977 --- . In 1982, Mul1er-Oerlinghausen * reported memory impair­
ment in fifty per cent of lithium treated patients. However, this
percentage is similar to that of patients complaining of poor memory
4 30
while treated with anti-depressants other than lithium ' . More
recent research has shown prolonged lithium treatment not to induce
memory disturbances
4.31 Certain lithium treated patients complain 
4 2
of a change of libido, usually a reduction .
Reports of diminished creativity in the artistic patient treated with
lithium have been documented ’ but have as yet not been verified ’ .
More subtle side effects, obviously difficult to demonstrate objectively,
such as blunting of the emotions, and lowered emotional responsiveness
4 33
with lithium therapy have been reported ' .
Schou in 1966, himself described the experience of indifference and "a
4 34
certain passivity" after self-administration of lithium ‘ . Lithium
4 32
is considered not to cause any personality changes ' .
37.
4. 6.7 Metabolic and Endocrine Effects
4. 6.7.1 Weight Gain
An increase in weight occurs in twenty to thirty-six per cent of
4 6 4 8
lithium treated patients ' ’ * . This gain is usually moderate
but twenty per cent of patients may display a gain as great as ten to
4 2 4 4
fifteen kilograms ' ’ * . The increase in weight is secondary to
increased tissue mass and independent of any oedematous changes.
Thirst and increased caloric intake may play an important role. It
is also possible that administration of lithium results in decreased
lipolysis by inhibiting adenylate cyclase, thus causing direct stimu-
4 35
lation of lipid deposition in the individual lipid cells ‘ . By
limiting caloric intake and assuring an adequate salt intake this side
4 2
effect can safely and effectively be treated ' .
4. 6.7.2 Lithium and the Thyroid
Lithium results in a benign reversible diminuation of the concentrations
of circulating thyroidal hormones. Data suggest a decrease of serum-
protein bound iodine (PBI) * , of free thyroxine (T4) ‘ , and of
4 3 131
tri-iodothyronine (T3) ’ , while the twenty-four hour I uptake is
4 37
increased ’ . These changes result in a negative feedback leading
to an increase in thyroid stimulating hormone (TSH) production, or an
autoregulatory mechanism resulting in the slow return to base line values
4 38
of the thyroid hormones ' . In individuals with underlying thyroid
dysfunction this insult produced by lithium further compromises the 
output of thyroid hormone. Thyroid pathology then occurs as a result 
of heavy stimulation of the thyroid tissue by TSH. Research into 
thyroid hormone releasing factor (TRH) has demonstrated that the anti­
thyroid effects of lithium are not due to any inhibitory effect on the
pituitary, but that the drug exerts its antithyroid effect at thyroidal 
4 7 4 39
level ' ’ ' , where lithium's concentration is four times greater than
that in serum. Lithium's likely mode of action at cellular level
involves a blocking of TSH - induced conversion of ATP to c-AMP or 
inhibiting c-AMP itself
38.
4.7
Thyroid pathology developing during lithium therapy falls into a wide
variety of metabolic categories. Schou studied 330 patients treated
with lithium for periods from five months to two years. He found
twelve subjects with euthyroid goitre, i.e. three and a half per cent
Shopsin found mixed thyroid pathology (euthyroidic and hypothyroidic
goitre, and hypothyroidism alone) in eleven per cent of seventy-seven
4 34
patients treated from three weeks to three years with lithium alone ‘
Other researchers have demonstrated varying incidences of thyroid
enlargement. In 1982, Martino found in a small sample study an
4 40
incidence of goitre as great as sixty per cent ’ .
The frequency of lithium-induced myxoedema is estimated at four to
4 41
thirty per cent of lithium treated subjects ' . A similar percentage
4 8
increase of TSH is also found ‘ which returns to normal in fifteen per 
cent. Should this level remain high for three to six months, it
implies impaired thyroid reserve, thus requiring thyroid hormone
i + 4.8replacement .
4 38 4 42
Lithium has also been reported to cause hyperthyroidism ' ’ * .
with a predicted transient rebound thyrotoxicity on withdrawal of
1 i thi urn 4.37 Reports of lithium associated Hashimoto thyroiditis 
4 2
have also been documented * .
Uni or bilateral exophthalmos has been reported in nine to eleven per
cent of lithium treated patients with the degree of proptosis unrelated
4 42
to the serum lithium level ‘ . Some authors assume - on the strength
of animal teratogenic studies - that lithium may act directly on the
4 43
retro-orbital tissues * .
All these conditions are fortunately readily reversible as the case may
be, either by discontinuation of lithium or when thyroid hormone is
4 44
administered concurrently with lithium ’ .
4.6.7.3 Lithium and the Parathyroid
Lithium also influences the secretion of parathyroid hormone, infrequently
4
resulting in elevated circulating parathyroid hormone and hypercalcaemia
39.
Several reports of lithium associated hyperparathyroidism have been 
4 42 4 45 4 45
documented while other researchers have demonstrated
4 47 4 48
the occurrence of lithium-induced parathyroid adenomas * ’ * .
Hyperparathyroidism may lead to osteoporosis and nephrocalcinosis
while hypercalcaemia greater than 12 mg/dl is associated with a variety
4 46
of psychiatric symptoms, e.g., agitation, psychosis and depression ' ,
Treatment of lithium- induced hyperparathyroidism initially consisted
of surgery, but since the benign nature of this condition had been
4 45
recognised a more conservative attitude has been adopted ' .
4.6.7.4 Lithium and Carbohydrate Metabolism
Initial reports assumed that lithium had a favourable action on diabetic
4 3  4 49 4 50
patients ' , and this theory continues to the present ' ’ ' .
Heninger, in 1970, demonstrated that the administration of lithium
resulted in a decreased tolerance to glucose in some lithium treated 
4 51
patients ' . A reversible lithium-related increase in blood glucose
4 52
was reported by Shopsin in 1972 ‘ . Research into animal pancreatic
islet cells has demonstrated a marked lithium-induced increase in nuclear
4 7
size of A-i cells ‘
metabolism are either inhibited or stimulated
, while many enzymes related to carbohydrate
4 3
' . The net result
indicates that lithium increases glycogen synthesis and possesses insulin- 
4 3
like properties ’ .
4.6.7.5 Lithium and Adrenocortical Activity
Platman reported a significant increase in morning cortisol levels during
4 53
lithium treatment. This increase appeared to be dose related ’ .
Shopsin reported lithium-induced increases, in a normal volunteer, in 
both morning and evening cortisol levels. These levels rose progres­
sively during treatment over a three week period. The author also
demonstrated a normal cortisol response after dexamethasone suppression
4 54
both before and after lithium ingestion * .
40.
4.6.7.6 Lithium and Growth Hormone (SGH)
In 1970, Heninger and Mueller demonstrated significant elevations of 
, 4 5 1
SGH during lithium therapy ' . An abnormal response by SGH to TRH
4 55
injection after two weeks of lithium therapy was also reported ' .
4.6.7.7 Lithium and Prolactin
Prolactin secretion is inhibited by the dopaminergic system, and
4 56
stimulated by the serotoninergic system V  . Both these systems
are apparently influenced by lithium, yet prolactin is considered
4 3
unaltered by lithium ‘ . This is substantiated by later research
4.57
4.6.8 Osseous Effects
Lithium is found in bone at concentrations higher than lithium serum
levels, and appears to accumulate more rapidly in immature bone ' .
Some animal studies have demonstrated lithium to have an inhibitory
4 58
effect on bone growth * - an implication to be heeded when treating
adolescents with this drug. Arthritis as a side-effect of lithium
4 59
toxicity has been reported by Black in 1984 ‘ .
4.6.9 Quincke's Oedema
An intermittent oedema located in the feet and ankles, more rarely in 
4 27
the face ‘ , and associated with an increased urinary aldosterone,
develops in ten per cent of lithium treated patients. The oedema
occurs particularly in subjects treated with a hiqh sodium diet or with
4 27 ~
thioridazine ’ . Administration of an aldosterone-antagonist
diuretic (e.g. spironolactone) consistently removes the oedema .
4.6.10 Renal Effects
Lithium produces two distinct categories of renal effects.
41.
4.6.10.1 Polyuro-polydypsic Syndrome
4.3
4.3
In more than fifty per cent of patients starting lithium treatment
a benign, vasopressin-resistant diabetes insipidus-like syndrome is
observed. It may appear or reappear in about twenty five per cent
4 7
of all lithium treated patients ‘ . Polydypsia is initially often
limited to a mere sensation of thirst, but may increase to a frank polyuro-
4 2
polydypsic syndrome attaining proportions of five to eight litres daily '
During this excretion of huge urine volume, the creatinine clearance and
4 7
lithium clearance remain constant ' , thus requiring no adjustment of
lithium dosage. The syndrome is regarded as a benign side effect 
without any specific remedy, and reversible on discontinuation of lithium.
Animal studies have demonstrated polydypsia to be abolished by bilateral
nephrectomy or ligature of the ureters ’ , suggesting the -Syndrome to be
the result of increased plasma renin activity. Dousa assumed that
lithium reversibly inhibited renal adenylate cyclase. The enzyme
converts ATP to c-AMP and in turn mediates vasopressin (ADH) response
on a cellular level Animal studies by Christensen indicate ADH
blockade as the only mechanism which results in the appearance of the
4 61
polyuric syndrome ' . A human controlled study by Waller in 1983
4
upholds the hypothesis that lithium influences adenylate cyclase activity
A recent animal study by Mailman demonstrated that polydypsia resulting
from the administration of lithium required intact nigrostriatal dopaminergic
fibres. The author postulated that the polydypsic syndrome did not
4 63
simply result from the lithium induced polyuria * .
4.6.10.2 Lithium and Nephropathy
4 64
Animal studies have demonstrated a direct toxic renal effect ‘ of
4 65
lithium, especially in sites low in mitochondria ' . Initial alarming
reports in humans of nephropathy appeared in 1974. Ten of fourteen
patients, all having suffered one or more episodes of lithium toxicity
showed an increased proportion of sclerotic glomeruli, focal nephron
4 30
atrophy, and interstitial fibrosis ‘ . That report generated inten­
sive research into renal function in patients on long-term lithium.
Burrows in 1978, demonstrated a tubulo-interstitial nephropathy, and 
suggested that lithium intoxication was not a prerequisite for the
cn
42.
occurrence of nephropathy In 1979, Hullin examined urinary
beta-microglobulins and found no difference between the control and
4 64
lithium treated groups ' . In 1979, Kincaid compared renal
biopsies of sixteen patients on prolonged lithium therapy, without
toxic episodes, to matched controls. He demonstrated no difference
between the pre-lithium and during-lithium biopsies. However, a
difference between biopsies from patients with an affective disorder
and from the control group was reported, implicating other psychotropic
4 67
drugs in the production of this syndrome ' . In 1979, the World
Psychiatric Association concluded that "the risk of lithium nephropathy
4 68
in the absence of lithium toxicity was minor" * . Vestergaard in
1979, assumed that the effect of lithium on the glomerular filtration
4 69
rate was moderate and progressed slowly * . In 1980, Gerner demon­
strated a poor correlation between the duration of lithium treatment
4 70
and urine osmolality ‘ . In 1980, Coppen, in a controlled study
reported little evidence of severe renal function impairment after
prolonged lithium therapy. He noted, however, an increased urinary
volume and a decreased concentrating ability of the kidneys in lithium 
4 71
treated patients * . Hullin, in 1980, advocated the lowest thera-
4 72
peutic lithium level to prevent nephropathy ‘ . Walker, in 1982,
presented a correlation between the degree of nephropathy and the duration
of lithium treatment. He assumed the lithium treated group of patients
to show an acute specific tubular lesion - dilation and microcyst forma- 
4 73
tion ’ . Wallin, in 1982, from a survey of renal function in 278
patients on long-term lithium treatment, demonstrated that the filtration
rate decreased as a function of the duration of the treatment. The
author concluded that severe impairment of renal function was uncommon
4 74
in well-controlled patients ' . Kalina, in 1984, documented a rever-
4 75
sible steroid treatable lithium induced nephrotic syndrome ’ . Waller,
in 1984, concluded that the relationship between lithium and irreversible
4 75
renal damage still remains unclear ‘ .
4.6.10.3 Conclusion
Judging from these reports, it appears that certain individuals are at 
risk to develop lithium-induced nephropathies. Susceptible patients
43.
may include those who :
(i) have pre-existing renal disease
(ii) are receiving concomitant treatment with other drugs
(iii) have sustained one or more episodes of lithium toxicity, and
(iv) polyuric patients seem at higher risk
As sound medical and legal advice, certain precautions are recommended 
to minimize the risk of possible renal damage :
1 . 
2 .
3.
4.
5.
6 .
Obtain a history of the renal state.
Assess the renal function prior to lithium treatment by -
(i) urine osmolality.
(ii) estimate the creatinine clearance, using
4 64
the Cockroft equation ’ .
Creatinine Clearance =
(140 - age) (weight kg)
(72) (serum creatinine)
Maintain the lowest therapeutic lithium level.
The use of slow-release preparations is preferred.
Patients with polyuria should not restrict their 
fluid intake, as dehydration may result.
Any changes noted in the creatinine clearance should 
indicate evaluation by a nephrologist.
4. 6.11 Lithium Teratology
Women being slightly more likely than men to suffer depressive episodes
4 77
which typically begin and unfold during the reproductive years ‘ ,
are guaranteed to be exposed to the effects of lithium. The drug 
crosses the placenta, with an equilibrium maintained by this barrier 
and thus their foetuses also will have to sustain the same influence 
of this ion
44.
Much research on sea urchin eggs, snail eggs and chicken embryos have
produced evidence that lithium exerts part of its teratogenic effect
by inhibiting deoxyribonucleic acid (DNA) ' . Research on higher
developed mammals have indicated that lithium disorganises developing
ectodermal structures, particularly the cephalic end of the growing 
4 79
neural tube ‘ . These specific teratogenic effects of lithium
result in cleft palate in mice and have been demonstrated to be dose 
related .
As animal studies do not necessarily indicate that similar effects may
4 8 1  4 1 2
be produced in humans, Jarvik, in 1971 ’ , and Genest in 1972 '
performed studies on human chromosomes. They suggested that lithium 
in therapeutic concentration had no significant effect on human 
chromosomes. In 1968, Mogens Schou, from a small sample of six 
infants, assumed that lithium had a low, if indeed any, teratogenic
4 gg
effect ‘ . In a later small follow-up study he concluded that
foetuses exposed to the effects of lithium were at no greater risk of
4 83
developing anomalies than the control group ' . Material gathered
by the Scandanavian Lithium Baby Register and by the International Register
of Lithium Babies bearing on the possible teratogenic effect of lithium
administration, indicated the incidence of congenital malformations
attributable to lithium at slightly more than ten per cent comoared to
4 30
three per cent in the normal population ‘ . A slight trend towards
4 30
cardiovascular malformations, notably Epsteins anomaly, was noted ' .
In 1982, Filtenberg described a neonate with lithium induced hypotonia,
goitre and increased pulmonary vascular resistance Kallen, in
1983, from a study of 350 bipolar woman, found the lithium-treated mothers
to have delivered babies with a statistically significant higher rate of
congenital malformations. A higher rate of perinatal deaths was also 
4 85
reported ‘ . Wilson, in 1983, reported on a neonate with lithium-
4 86
induced atrial flutter . In 1983, Morrell reported the occurrence
of lithium induced functional lesions of the cardiovascular, renal and
neuromuscular systems, which settled after a period of one year. Some
4 87
developmental delay persisted ' . Mallinger, in 1983, demonstrated
that lithium may have an effect even when administered during the last 
month of pregnancy .
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It is to be noted that the creatinine and lithium clearances rise
by thirty to fifty per cent during the last half of pregnancy, to
abruptly fall again at the time of delivery to pre-pregnancy levels.
This phenomenon may lead to lithium underdosage during pregnancy, and
to overdosage and lithium intoxication at the time of delivery.
Administration of lithium should therefore be discontinued in the lithium
treated pregnant women a few days before the expected date of delivery,
4 3
and to be resumed only three days after delivery ' .
4.6.11.1 Conclusion
These reports clearly indicate that the administration of lithium - unless 
the potential benefits outweigh the risk - ought to be avoided during 
pregnancy, especially during the first trimester.
4.6.12 Lactation
Lithium concentration in the mammary milk of lactating lithium-treated
mothers is thirty to 100 per cent that of serum. The breast fed
neonate may attain serum lithium concentrations approximating that found
4 27
in the mother's milk ' . The lithium treated mother should therefore
be discouraged to breast feed.
4.6.13 Testicular Effects
4 89
Lithium administration may adversely affect the motility of human sperm ’
4 90
but Levin demonstrated in 1981 that lithium had no effect thereupon ’ .
However, lithium toxicity has resulted in severe, prolonged but reversible
4 91
primary testicular failure ' .
4.6.14 Withdrawal Effects
Mogens Schou in 1968, reported that lithium-treated patients showed no
altered tolerance to, nor become sensitized to the effect of lithium.
4 34
Abstinence symptoms were not demonstrated ‘ . This was verified in
1982 by Christodoulou who raised the possibility of a neurochemical rebound
4 92 4 95
phenomenon ' , which was previously discounted by Baastrup in 1970 * .
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A recent anecdotal report by King, strongly underscores the occurrence
of withdrawal symptoms surfacing two to three days after lithium
discontinuation. These consisted of transient anxiety, irritability,
and emotional hyperreactivity in nineteen per cent of lithium treated 
4 94
patients ' . Findings from a report by Sashidharan in 1983 suggested
4 95
that lithium produced no withdrawal symptoms, and no rebound phenomenon .
4.7 Lithium Intoxication
4.7.1 Symptomatology
Lithium poisoning develops when more lithium is administered than can be
excreted by the kidneys. Lithium intoxication is not always related
to serum lithium levels, indicating that some individuals may possess some
4 96
intolerance or abnormal sensitivity to the drug ' . Impending toxicity
is usually a gradual phenomenon, signified by aggravation or reappearance 
of side effects seen initially at the start of lithium therapy, e.g., the 
initial fine tremor becomes coarse and is often accompanied by fascicula-
tions 4.35 This is followed by prodromal symptoms of a moderately
4.7
severe nature - sluggishness, confusion, anorexia, emesis, and diarrhoea
As toxicity increases the presence of an acute brain syndrome becomes
more apparent with ataxia, rombergism, dysdiadochokinesis and nystagmus -
4 7
implying cerebellar dysfunction ’ . In conjunction with neuroleptics,
4 97
lithium is capable of inducing the Neuroleptic Malignant Syndrome ‘ .
Reversible EEG changes in the form of slowing, the appearance of theta and
4 43
delta waves, and of sharp spikes occur ' . Seizures may precede coma
4 2
and eventual death * . It is clear that in humans the CNS is the
principal target of lithium intoxication. This neurotoxicty correlates
well with the appearance or severity of EEG changes, although the erythrocyte 
(RBC)-serum-lithium-ratio may serve as a better predictor
4.7.2 T reatment
The basic approach to the treatment of lithium intoxication rests on 
several sound principles.
4 7 .
(1) Prevention : i) by the exclusion of unsuitable patients
ii) by proper administration of the drug
iii) and by proper control of the serum 
lithium concentration
(2) Elimination :
In mild states of lithium intoxication, elimination of the drug would
entail immediate discontinuation of lithium. In a more moderate
toxic state, lavage in the alert patient should be performed within six
hours after the last ingested dose of lithium. As no specific antidote
is available, forced or osmotic diureses by means of aminophyl1 ine, urea
4 99
or mannitol may be helpful ' . The administration of sodium-chloride
4 7
and potassium-chloride appears to be of limited value ‘ . In instances
of severe lithium intoxication the benefits of dialysis, either peritoneal
4 100
or haemodialysis, are superior to fluid therapy or to forced diuresis ‘ .
Peritoneal dialysis produces an additional clearance of fifteen millilitres
per minute (ml/min) while haemodialysis augments the clearance by fifty 
4 3
ml/min * . However, repeated dialysis may be indicated as the serum
i , . . . , ... ■ , , , . . . . . . . .  4.101,4.102,4.103
values rebound due to lithiums large volume of distribution
(3) Correction of fluid and electrolyte imbalance
(4) Regulation of kidney function
(5) General supportive measures.
Patients who recover from states of lithium poisoning, even those who 
were previously comatose, are considered to suffer no permanent sequelae 
but a recent report by Apte had demonstrated two cases of permanent
neurological deficits following relatively uncomplicated episodes of
, .., . . , . . . 4.104
lithium intoxication .
4.2
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4.8 Lithium Levels of Toxicity
To avoid toxic reactions, the serum lithium levels should not exceed
4 3 4 7
a limit of 1.5 mEq/1 ' ’ ’ . This, however, is not an arbitrary
4 105
figure as several authors cite an upper limit of 2 mEq/1 ‘ , while
others have advocated dropping the lower limit to 0,5 mEq/1 
Clinical experience in South Africa has suggested serum lithium levels 
lower than 1 mEq/1 to avoid toxicity. This phenomenon might be 
produced by the country's subtropical climate
As a warning of impending toxicity the determination of serum lithium 
levels appear to have only limited usefulness. Evidence has accumu­
lated that the elevated concentration of lithium in RBC may more accu­
rately correlate with incipient toxicity or the severity of side 
a q i qb a m g
effects This RBC - serum ratio, coupled with
lithium-sodium transport across RBC membranes has been demonstrated 
to be under genetic control, with evidence of an autosomal polymor­
phism
4.110, 4.111, 4.112
A correlation between also the white
blood cell (WBC) lithium concentration and the severity of side effects
4 113
has been reported ‘ .
Research into RBC and WBC-lithium interactions, with its implication 
in the mechanism of lithium's mode of action, and clarification of the 
genetics of the affective disorders, is as yet obscure and in its infancy.
49.
CHAPTER 5
Lithium and Mania
5.1. The Effect of Lithium on the Normal Volunteer
Moqens Schou conducted a series of three studies to ascertain the
5 1
effect of lithium on normals ' .
5.1.1 .
In the first study conducted in 1968, six healthy volunteers received 
either a placebo or 25 m Eq 1 ithiurn dai 1 yfor a period of one week.
After a three week drug free period the procedure was repeated in a 
crossover fashion. The most frequently recorded symptoms during 
lithium and placebo periods were fatigue and muscular heaviness.
However, these signs presented more frequently during the lithium period.
5.1.2 .
In their second study, the authors self-administered 25m Eq. of lithium 
daily for periods of three to six weeks. They noted no affective 
changes nor any influence on intellectual function.
5.1.3
In the third study the authors increased the self-administered dosage 
to 50m Eq of lithium daily for a period of one to three weeks. 
Irritability, emotional lability, coupled with indifference and mild 
general malaise were noted. A certain passivity was also described.
5.1.4
In 1979, Friedman found prolonged lithium treatment to have no impair-
• • R ?
ment on cognitive functioning
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In 1979, Kropf studied the effects of lithium in twenty-four healthy
young male volunteers. They reported themselves to be less active,
more bored, socially less involved with others and with a decreased
. 5 3
capacity to initiate new activity ' .
5.1.5
5.1.6 Conclusion
A1though reports of the effect of lithium on normals are conflicting, 
the idea that greater dosages of lithium influence cognitive functioning 
appears to have some validity.
5.2 Lithium in the Treatment of Mania
This section reviews the major studies of lithium as a treatment for the 
manic phase of bipolar affective disorder. The studies comparing 
lithium to neuroleptics are of special importance because they bear on 
the question of the specificity of lithium against the manic syndrome.
5.2.1 . Uncontrolled and Single Blind Trials
5. 2.1.1 .
Cade is credited with the discovery in 1949 of the antimanic properties
of lithium. In an uncontrolled study of six manic patients he
5 4
reported an overall improvement rate of 100 per cent ‘ .
5.2.1.2
In 1951, Noack, in an uncontrolled study of thirty manic subjects 
established that eighty-three per cent responded favourably to lithium
51.
In 1954, Glesinger reported a lithium induced improvement rate in
5 6
seventy-one per cent of his twenty-one manic patients .
5. ?•1.3
5.2.1.4
A study by Schou in 1959 demonstrated that seventy-six per cent of 
119 manic patients had a beneficial response to lithium treatment
5.2.1.5
In 1960, Kingstone reported a lithium induced improvement rate in
5 6
ninety-four per cent of seventeen manic subjects " .
5.2.1.6 & 7
Lithium induced improvement rates of sixty-eight per cent and ninety
5 7
per cent were recorded in 1966 by Fieve and Schlagenhauf respectively ‘
5.2.1.8 Conclusion
In general, these uncontrolled studies represent the early clinical 
trials of lithium. Most of these do not use rating scales for the
evaluation of clinical response. In spite of this shortcoming it is
still impressive that these trials consistently demonstrate a high 
incidence of response.
5.2.2 Placebo Controlled Trials
5.2.2.1
In 1954, Schou and Voldby, in a pioneering attempt to document objectively 
the effects of lithium on manic symptomatology, published the first 
double-blind controlled study. This trial was conducted with thirty- 
eight manic patients, of whom thirty were described as "typical" and 
eight as "atypical" manics. Administration of lithium or placebo 
was alternated randomly every two weeks. Lithium dosage was adjusted 
accordingly so as to maintain serum levels ranging from 0,5 to 2,0 m Eq/1.
52.
The results indicated that thirty-seven per cent of the subjects had
a positive benefit from lithium, forty-seven per cent showed a possible
beneficial response, while sixteen per cent received no benefit.
Three different lithium salts were used - carbonate, chloride and citrate,
5 5
without anv differences being noted among the three types ' .
5.2.2.2
In 1953, Maggs, in a placebo-controlled double-blind study randomly
assigned twenty-eight manic patients to two groups. One group was
treated with lithium for two weeks, followed by a medication free period
of two weeks, and placebo for a further two week period. The second
group was treated similarly in a crossover design. The author noted
that the manic symptomatology diminished significantly, specifically
during the second week of lithium treatment. He concluded that lithium
5 6
was significantly superior to placebo in the treatment of mania * .
5.2.2.3
In 1958, Fieve conducted a placebo-controlled double-bling study of
thirty-five manic patients. He demonstrated that lithium produced "good"
results in eighty per cent "equivocal" results in six per cent and no
5 8
improvement in fourteen per cent of the subjects ' .
5.2.2.4
A placebo-controlled, double-blind study by Bunney and his associates in
1958 offered longitudinal data on only two manic patients. Both
subjects were treated in a random fashion with either lithium or placebo.
In this study the sensitivity of manic symptoms to temporary withdrawal
of lithium medication was demonstrated. The change occurred within
5 9
even the first twenty-four hours of withdrawal of lithium ' .
5.2.2.5
In 1969, Goodwin interposed periods of placebo with lithium periods in
each of twelve manic patients. During the latter periods the lithium
serum concentrations were maintained between 0,8 to 1,3 m Eq/1. Results
showed that eight patients had a complete response, one a partial response
5 10
and three (possibly schizoaffective) ' deteriorated ’ .
53.
5.2.2.6
In a placebo-controlled, double-blind study, Stokes and his associates 
in 1971 alternated lithium and placebo for rather short periods of 
seven to ten days in thirty-eight manic-depressive patients. A mean 
serum lithium level of 0,93 m Eq/1 was achieved. The trial indicated 
that seventy-five per cent of patients improved after seven days of
lithium therapy and that eighteen per cent deteriorated. An equal
number of patients improved and worsened during the placebo periods
5.11
5.2.2.7 Conclusion
Mania is a cyclic phenomenon and generally remits spontaneously within 
5 12
some months ‘ . It is considered unresponsive to the subtle environ­
mental or interpersonal factors which contribute to placebo response 
5 6
rates ' . The controlled studies have indicated that the manic 
symptomatology subsided within a week or two of lithium treatment.
It is thus unlikely that the rapid disappearance of manic symptoms during 
the first two weeks of lithium treatment in the majority of patients 
would be due to chance or to a placebo effect. Furthermore, the results 
of these trials corroborate the findings of the uncontrolled studies, and 
in addition, demonstrate the superiority of lithium to placebo in the 
treatment of mania.
5.2.3 Neuroleptic Controlled Trials
The efficacy of lithium established in the treatment of mania, the
question concerning the role of 1 ithium changed to the issue of its
~ 5 1 3
specificity and its collation with other drug therapies ‘ .
5.2.3.1
In 1968, a double-blind study demonstrated that lithium was "clearly
5 7
superior" to chiorpromazine in the treatment of mania ‘ .
5 4 .
In 1970, Platman conducted a double-blind three week trial with thirteen 
manic patients. The subjects were treated with lithium and compared 
to ten manic patients treated with chlorpromazine. The groups were 
randomly assigned to three weeks of either lithium or chlorpromazine, 
preceded by a two week period of placebo. Plasma lithium levels 
were maintained at 0,8 m Eq/1. The majority of the lithium treated 
patients were discharged thereon. None of the chlorpromazine treated 
patients could be discharged on chlorpromazine. The author assumed
lithium to be only slightly superior to chiorpromazine in the treatment
, . 5.14
of m a m a  .
5 . 2 . 3.2
5.2.3.3
In 1970, Spring and his associates studied fourteen manic patients in
a double-blind trial comparing the effectiveness of lithium carbonate
with chlorpromazine. Six of seven lithium treated subjects responded
to lithium. Three of five chlorpromazine treated patients responded
to this drug. The two chiorpromazine resistant patients were crossed
over to lithium and both had a remission of manic symptoms. The one
lithium resistant subject was crossed over to chiorpromazine without
response. In this small study, eighty-nine per cent of the subjects
showed a responsiveness to lithium, while fifty per cent of the chlor-
5 15
promazine group benefitted from the neuroleptic * .
5.2.3.4
From a collaborative project with the National Institute of Mental Health
in 1972, Prien and his associates analysed data from 255 manic-depressive
patients. They concluded that chiorpromazine was superior to lithium
among the "highly active" group, particularly in the first week of treatment.
Among the "mildly active" group lithium appeared to be the slightly better
5 16
treatment, particularly from the second week of treatment ’ .
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5. 2. 3.5
In 1975, Takahashi documented a double-blind multi-institutional
Japanese st•1 dy comparing a low dose lithium (mean serum level of
0,57 m Eq/l)to chlorpromazine in the treatment of eighty manic patients.
Results from this trial indicated that thirty-two per cent of the
lithium treated patients and twelve per cent of the chiorpromazine
subjects improved after five weeks of treatment. Lithium, according
to the researchers, behaved in a "pure" antimanic fashion, whereas
chlorpromazine acted as a general sedative, suppressing the hyperactivity
5 17
without altering the underlying manic symptomatology ' .
5.2.3.6
Shopsin, in 1975, in a double-blind study compared the effectiveness of 
lithium to chlorpromazine and also to haloperidol in the treatment of mania. 
A total of thirty manic patients, ten in each group, were randomly assigned, 
following a seven day washout period, to one of the three drugs. These
were administered for a period of three weeks. Serum lithium levels of 
1,0 to 2,0 m Eq/1 were achieved. Analysis of the obtained data revealed 
that lithium markedly improved seventy per cent, chiorpromazine ten per 
cent, and haloperidol twenty per cent of patients. Haloperidol decreased 
hyperactivity to a greater degree than either chiorpromazine or lithium.
In the normalization of mood and ideation both chiorpromazine and halo­
peridol were outranked by lithium which also obtained a superior differen-
, . , ,. , . 5.18
tial discharge rate .
5.2.3.7
5.12
In 1980, Garfinkel in a haloperidol controlled study demonstrated that 
ten haloperidol treated patients responded as well as ten manic patients 
receiving the 1ithium-haloperidol combination. The seven patients 
treated with lithium alone responded poorly in seven days of treatment 
This period may be considered inadequate for a trial of lithium, consider­
ing that a host of studies have indicated that lithium's main disadvantage 
in the management of the severely disturbed is in fact the slow onset of 
its therapeutic action - some five to ten days 5.16, 5.18, 5.19^
The results from this study induced its authors to recommend haloperidol 
as the drug of choice in the treatment of mania.
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5. 2. 3.8
A later double-blind study conducted by Braden in 1982, compared 
the effectiveness of chlorpromazine to that of lithium. This
5 16
study produced similar observations previously demonstrated by Prien ' ,
i.e., that lithium was effective in the treatment of the "acutely psychotic
5 19
patient" who was not overactive ' .
5.2.3.9 Conclusion
These studies provide abundant evidence that lithium is superior or equal 
to neuroleptics in the treatment of mania. Lithium also appears 
to possess a specific antimanic effect, which is produced more slowly 
than the neuroleptics.
This lag period probably accounts for the reported advantage of neuro­
leptics over lithium in the initial management of highly active manics. 
Most of the evidence suggests that lithium alone is the treatment of 
choice for those manic patients whose hyperactive behaviour can be managed 
during the lag period before lithium begins to exert its effects.
For those manic patients whose hyperactivity requires immediate control, 
neuroleptics in combination with lithium are the preferred procedure. 
However, in an evaluation of any treatment in medicine, the effectiveness 
of the drug in terms of reduction of morbidity has to be balanced against 
its adverse effects and economic costs. Evidence abounds that lithium 
reduces the morbidity associated with affective disorder, while it is 
estimated that the drug has saved the United States of America more than
2,5 billion dollars in direct mental health treatment costs and 1,8 
billion in productivity, over the first ten years since its introduction
5.20
5.3 Serum Lithium Levels in Mania
Results from the studies have demonstrated that a successful outcome in
the treatment of the acute manic phase requires a serum lithium level
between 0,8 to 1,2 mEq/1. Certain authorities advocate higher serum 
5 21
lithium levels ' . Some researchers consider a level under 0,9 mEq/1
5 22 5 23
ineffective ‘ , while others advise levels as low as 0,5 m Eq/1 * .
57.
5.4 Predictive Variables in Lithium Therapy
Several researchers, having realized that the serum lithium level 
afforded no indication of the desired response, have analyzed data 
attempting to identify indices of a favourable response to lithium therapy.
A lithium diuresis was initially considered a valuable prognostic symptom
Retention of lithium at the initiation of treatment was considered a
5.24
5.24
valuable prognosticator The importance of these variables however,
are rooted rather in the adjustment of the dosage of lithium during the 
5 21
treatment period ‘ . Lower ATPase activity and a high RBC to plasma
5 25 5 25
lithium ratio have been considered to possess some prognostic value ‘ ’ '
Lithium induced increases of RBC choline levels were considered also to
5 27
have value in predicting lithium responsive patients * . These hypo-
5 28 ~
theses however, have not been verified ‘ . The RBC glycine levels
5 29
have recently been implicated as having some predicative value * .
Other indices bearing relationship to the outcome of lithium treatment
5 30 5 31
have included a family history of affective disorder ' ’ ' , especially
a history suggestive of X-linked dominant transmission of bipolar illness.
A family history of lithium-responsiveness appears also to act as an
5 32
auspicious prognosticator ‘ . These patients tend to experience the
illness early in life, while those with a negative family history have a
5 33
later onset of the illness and respond less well to lithium ' .
Research into premorbid personality has yielded some results. Taylor 
found that patients with a cyclothymic premorbid personal i ty were more
5 34
responsive to lithium than those with a dysphoric or schizoid personality * 
The presence of a high score on the Neuroticism Scale of the Esyneck
5 30
Personal ity Questionnaire has been assumed to have some predicative value * .
5.5 Mania Refractory to Lithium
Most trials conducted on mania have indicated that lithium distinctly
improves seventy to eighty per cent of patients within one to two weeks.
Twenty to thirty per cent of manics, especially those who have suffered
5 33
four or more cycles per year ‘ are likely to be refractory to the 
5 35
drug . Alternatives in treating these lithium-resistant patients 
consist often of combinations with other drugs.
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5.5.1 Carbamazepi ne
Carbamazepine (CBZ) is the only anticonvulsant with a potential psycho- 
5 36
tropic effect ' . The drug is known to inhibit c-AMP, but the
5 36
psychotropic mechanism is yet unestablished * . Although some
adverse effects have been reported when CBZ is jointly administered 
5 37
with lithium ‘ , synergism between the two drugs has also been docu-
5 38 5 39 -
mented ‘ ’ * . From a study of five manic subjects diagnosed
by DSM III criteria, Inoue in 1981, reported that three patients res­
ponded to CBZ alone, while a fourth patient, unresponsive to this drug,
5 40
improved dramatically on the CBZ-lithium combination ' . In 1982,
Nolen in a small trial of twelve subjects demonstrated the safety of
this combination and its effectiveness in treating the lithium refractory 
5 41
bipolar patient ’ . Lipinsky in 1982, reported on the efficacy of
the use of the CBZ-lithium combination in three manic patients who were
5 42
unresponsive to either drug alone ' . The superior value of this
5 43
combination has been reported also by Keisling in 1983 * . Another
trial demonstrated CBZ to be more effective than chlorpromazine in the
treatment of manic episodes. The effectiveness, however, did not
5 44
extend to depressive states ’ . The efficacy of CBZ in depressive
5 36
episodes has recently been established * .
5.5.2 Conclusion
It appears that CBZ is now an establ ished adjunct to lithium treatment 
in the management of mania refractory to lithium. As prophylactic
treatment of bipolar disorder the efficacy of the drug is assumed to be
5 36
about seventy per cent ' .
5.5.3 Other Drugs
L-tryptophan has been successfully administered, singly and in a lithium 
combination, in the treatment of mania 5 *45, 5’46. Similar successful 
results have been demonstrated with reserpine 5 '47. Valporic acid, a 
potent inhibitor of amygdaloid kindling, has produced poor results ^ ' 44 
when used on its own in affective illness. Pimozide, bromocriptine, prop­
ranolol, vanadium, digoxin, methylphenidate, verapamil, and a host of other 
drugs have been reported to possess positive effects in the treatment of 
the lithium-resistant manic patient^'44.
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CHAPTER 6
Lithium and Depression
5 1] Lithium in the Treatment of Depressive States
The view that depression and mania may have important biological and 
clinical changes in common allowed for the possibility that a single 
drug could be effective in the treatment of both episodes. Following 
the findings of lithium's effectiveness in the treatment of the manic 
phase in bipolar illness, it is not surprising that its efficacy was 
put to the test in depressive states.
6.1.1 Uncontrolled Studies
Cade, in 1949, had already observed that although lithium seemed to
have weak anti-depressant properties, it had no beneficial effects in
6 1
the treatment of depressed patients . Noack, in 1951, noted the 
absence of any therapeutic response to lithium and suggested that
6 2
several depressed patients deteriorated when treated with lithium * .
Vojtechovsky in 1957, reported that eight out of fourteen ECT-refractory
6 1
depressives improved when treated with lithium ' . The following 
year Andreani reported that ten of twenty-four depressed patients improved
C n
on lithium0’*-. Five years later Hartigan also reported a favourable 
response to lithium in six out of eight manic-depressive patients 
diagnosed as depressed
In 1968, Dyson and Mendels conducted an open trial treating thirty-one 
patients of mixed depressive states with lithium. They reported no 
success with nine cases of neurotic depression or with three cases of 
involutional psychotic depression. They did however note that most
of the nineteen cases of bipolar illness-depressed phase did respond to
, .., . .... , 6 . 4
lithium within one week .
Za11, in 1968, reported on a group of depressed patients treated either 
with lithium alone or in combination with a tricyclic antidepressant.
6 0 .
They suggested that a combination of lithium with either a tricyclic
6 5
or a MAO-inhibitor was an especially effective form of treatment ‘ .
Van der Velde, in 1970, conducted an uncontrolled study of seventy-five 
patients who received lithium for a period of two weeks. Results 
from this study demonstrated a deterioration of the depressive sympto­
matology in eight patients
Nahunek, in 1970, conducted an uncontrolled German study with ninety- 
eight patients. The subjects were diagnosed as either endogenously 
depressed or suffering from melancholia. Fifty-four per cent of the 
patients improved, usually the less disturbed. The author also con­
cluded that lithium might be as effective as amitriptyline and imipramine, 
but less effective than desipramine and protriptyline, while all drugs 
were inferior to ECT
In an uncontrolled study, Noyes examined the effect of lithium citrate in
five depressed patients. Four became symptom free. Two of the 
four relapsed within forty-eight hours of placebo substitution. The
fifth subject showed only moderate improvement and also relapsed with
6 3
placebo substitution ’ .
Eyssette, in 1972, studied ninety-five patients of mixed depressive 
states, over a period of nineteen months. Results indicated that 
fifty-five subjects, usually of the bipolar depressed phase, improved 
on lithium. A rather poor response to lithium was displayed by 
patients suffering from neurotic depression. The researcher concluded 
that lithium had a major antidepressive action in especially the depres­
sive phases of bipolar patients. He also commented on the possibility 
that lithium gluconate might be more effective than the conventional 
lithium salts, and on the possibility that the antidepressant effect 
might be manifested only at rather low serum lithium levels
In 1 9 7 6 ,  Neubauer reviewed the cases of twenty d e p r e s s e d  patients treated 
with lithium over a period of four years, after having failed to respond 
to other treatment methods. Clinical improvement was usually evident
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within two weeks after the initiation of lithium. The author 
suggested that certain features appeared to distinguish the lithium 
responders as a depressive subgroup. These features included a 
depressive mood associated with anergia, inconcentration, and sleep 
disturbance. A history of premorbid obsessional personality traits 
and the presence of obsessional symptoms during the depressive illness
surfaced as distinctive features. The author claimed these symptoms
6 8
as favourable indices in the treatment with lithium .
6.1.2 Controlled Studies
6 . 1 .2.1
Hansen, in 1968, conducted a placebo-controlled, double-blind study of 
twelve endogenously depressed patients. From this two week trial the 
researcher reported lithium not to ameliorate depressive symptomatology
6.1 .2.2
In the same year Fieve compared the antidepressant effect of lithium 
with imipramine in twenty-nine bipolar patients who were acutely de­
pressed. This double-blind study comprised a two to four week 
placebo pretreatment period, after which the subjects were randomized 
to either lithium or imipramine for three weeks. No variation in 
depression scores occurred during the placebo period. The treatment 
period produced improved rating scores in both groups, that of the 
imipramine-treated group being greater than the lithium-treated group. 
The author concluded that while lithium showed at best a weak anti­
depressant action, imipramine showed a moderate-to-strong and certainly
6 9
superior antidepressant effect ' .
6.1 .2 .3
In 1969, Goodwin conducted a longitudinal double-blind study of thirty 
bipolar patients, of whom twelve were experiencing a manic and eighteen 
a depressive episode. Results from this study suggested that lithium 
might have antidepressant properties for the bipolar depressive subtype
6 2 .
6 . 1. 2.4
In 1971, Stokes published his results from a placebo-controlled, double­
blind study of the effect of lithium on bipolar illness. Eighteen 
patients were treated for a rather short period of seven to ten days on 
either lithium or placebo. The author demonstrated a significant 
advantage of lithium over placebo in mania, but in depression the rate
of improvement was insignificant - fifty-nine per cent as compared to
6 11
forty-eight per cent with placebo ' .
6. 1. 2.5
In 1972, Goodwin conducted a second placebo-controlled, double-blind 
study. Sufficient details of the treatment procedure are lacking.
In spite of this the researcher reported evidence that lithium exerted 
a significant antidepressant effect, especially in the depressive phase
r , ■ ,  . , ,  6.12
of bipolar illness .
6 . 1 . 2.6
In 1972, Mendels assessing the effect of lithium and of desimipramine in 
depression, studied twenty-four bipolar depressed patients in a double­
blind crossover study. The subjects were randomized to either lithium 
or desimipramine for two three-week periods. If a patient improved 
by fifty percent on the Hamilton Depression Rating Scale after three 
weeks of treatment with one or the other drug, the subject was continued 
on the same drug. If no improvement was evident the patient was 
changed to the other drug. At the end of three weeks nine of the twelve 
lithium-treated patients had improved, as had six of the twelve subjects 
on desimipramine. The author concluded lithium to be as effective as
desimipramine in "selected depressed patients'
6.13
6.1.2.7
Lingjaerde reported in 1974, that lithium administered concurrently with
a tricyclic antidepressant (TCA) in depressive states, seemed to improve
6 14
the therapeutic outcome ' .
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6.1 .2.8
The same year saw the documentation of a placebo-controlled trial by
Noyes of twenty-two patients of mixed depressive states. His results
indicated that thirteen subjects improved on lithium all six of the
bipolar group and seven of sixteen of the unipolar group. With the
6 4
substitution of placebo nine patients suffered a relapse ' .
6. 1.2.9
Watanabe, in 1975, studied forty-five patients of mixed depressive
states in an imipramine-controlled, double-blind trial. From the
results he assumed that lithium's antidepressant properties were as
6 15
effective as those of imipramine ’ .
6.1.2.10
In 1975, Baron assessed the antidepressant efficacy of lithium carbonate 
in a double-blind, placebo-crossover trial. The twenty-three depressed 
subjects consisted of nine bipolars and fourteen patients suffering from 
unipolar depression. After a one to two week placebo pre-treatment 
period, the patients received therapeutic dosages of lithium for nine­
teen days. If patients improved they were subjected to a further two 
week placebo period. During the trial five subjects experienced 
spontaneous remissions. Of the remaining eighteen, five responded un­
equivocally to lithium, four with bipolar and one with unipolar depression. 
Five subjects responded equivocally, i.e., three bipolars and two unipolars, 
while eight patients showed no response, i.e., one bipolar and seven 
unipolars. The author concluded that lithium was especially effective 
in treating the depressive phase of bipolar illness
6. 1.2.11
Worrall, in 1979, reported his findings from two controlled double-blind 
studies on sixty-three females suffering from either unipolar or bipolar 
depression. In the first trial lithium was compared with imipramine, 
and in the second, lithium in combination /vith tryptophan was compared 
with tryptophan alone. The results from the studies suggest that 
lithium alone or in the tryptophan-lithium combination had significant
6 4 .
antidepressant effects. At the end of a three week period, the
drug combination produced more uniform improvement than did imipramine.
6
Tryptophan appeared to be without discernable antidepressant activity
6.1 .2.12
Twenty-three patients, diagnosed according to the Research Diagnostic 
Criteria as major unipolar depression, were subjected to a Canadian study 
under the auspices of de Montigny in 1981. Of these subjects, eight 
were considered non-responders after a three week trial on tricyclic 
antidepressants (TCA). When lithium carbonate was added to their 
treatment regime all eight patients experienced a greater than fifty 
per cent improvement of their depression within forty-eight hours.
The author assumed an enhancement of the central serotoninergic system
as the basic mechanism of the improvement. He concluded that the
6 18
addition of lithium might be useful in patients refractory to TCA ' .
6.1.2.13
In 1982, Honore randomized forty-three endogenously depressed patients 
to either amitriptyline or to the combination of lithium with L-tryptophan. 
Both groups responded significantly and neither of the two treatment 
regimes could be regarded as superior. From this study it appeared
that lithium combined with L-tryptophan might be effective in the treat­
ment of endogenous depression
6.1.2.14
In 1983, de Montigny conducted two further studies to assess the use­
fulness of combining lithium with TCA's in the treatment of depressive 
patients unresponsive to TCA's. Lithium was added to five amitriptyline 
pretreated and five placebo pretreated patients, who had remained unim­
proved on these drugs after a two week trial. All five patients 
receiving amitriptyline experienced a greater than fifty per cent 
improvement within forty-eight hours after the addition of lithium.
One patient in the placebo group showed improvement. The authors 
again invoked TCA-induced sensitization of the central serotoninergic 
neurons as the mechanism resulting in improvement. In the s e c o n d  study 
the effect of lithium withdrawal was assessed in nine TCA-resistant
65.
patients who had shown a marked improvement forty-eight hours after the 
addition of lithium carbonate. Five of these patients relapsed five 
days after the discontinuation of lithium. Again the author emphasized 
that the addition of lithium was useful in patients refractory to tri­
cyclic antidepressants *
6, 1.2.15
To assess whether lithium might indeed augment the antidepressant effects 
of TCA's in non-responding patients, Heninger conducted a placebo-con­
trolled, double-blind study in 1983. Fifteen TCA-refractory patients 
were randomized to either a placebo addition or lithium addition group. 
The eight subjects of the lithium group showed significant improvement 
especially after ten days of lithium therapy. The seven placebo addi­
tion subjects showed similar improvement only when crossed over to 
lithium. This lithium-induced augmentation of antidepressant effect
was demonstrated in patients treated with desipramine, amitriptyline
. . . 6.21 '
and mianserin .
5.1.3 Conclusion
The results obtained from trials assessing the antidepressant effects 
of lithium hardly approximate the results obtained from lithium studies 
regarding its antimanic properties. Contradiction surrounds the 
question of whether lithium is an effective antidepressant. Several 
factors possibly contribute to the confusion, e.g. :
i) initial nosological inconsistencies, and
ii) the grouping of dissimilar depressive states in single 
entities. However, with the subclassification of 
bipolar and unipolar subtypes some evidence has appeared
indicating that the bipolar depressive subtype is lithium
• 6.7, 6.13, 6.16
responsive .
iii) as bipolar depressives frequently suffer from simultaneous
c  on
micromanic features ‘LL the administration of lithium may 
be cutting into the manic symptomatology causing overall 
improvement of the clinical depressive picture.
65.
iv) not all bipolar patients respond to lithium either 
in the depressed and/or manic phases. Similarly, 
imipramine is not effective for all unipolar patients.
It seems likely that bipolar depressive illness may in 
fact be a heterogeneous condition, clinically ' and 
genetically ^-24.
6.2 Predicative Variables in Depression
Despite the problem with nosology and research difficulties there is 
some evidence that a certain select group of depressed patients may 
respond to lithium. Several characteristic features of the depressed 
patient who may be lithium responsive include the following :
i)
ii)
iii)
iv)
v)
vi)
bipolarity,
lack of precipitating factors for the depression, 
decreased mentation,
a family history of affective illness
6.25
6.5
the presence of neurovegetative symptoms
a significantly higher RBC - plasma lithium ratio is 
found in depressive patients who respond to the drug
6.25
vii) research has suggested that the Minnesota Multiphasic
Personality Inventory might accurately predict the
antidepressant response in patients to lithium
6 25
but this remains unsubstantiated ' .
57.
CHAPTER 7
Prophylactic Lithium Maintenance Treatment
"Prophylactic action" implies the possibility that lithium administered 
continuously over a protracted period might prevent or ameliorate the 
recurrences of mania and of depression. The demonstration of this 
action has been hampered by ethical, methodological and nosological 
problems.
During the period of lithium administration for treatment of mania the
drug was administered to a patient experiencing fairly regular cycles
between mania and depression. This unexpectedly led not only to
diminution of the manic episodes but also to a clear-cut attenuation
of the depressive symptoms. M Schou, in 1956, thus concluded that
lithium exerted a therapeutic action in depression as well as in mania
Until 1967 anecdotal evidence of lithium's prophylactic properties
7 2
surfaced sporadically, e.g., reports from Hartigan and Baastrup ' .
7.1 Uncontrolled Studies
7.1. 1
In 1967, Baastrup selected eighty-eight patients from among a larger 
group of manic-depressive patients. Selection criteria included 
a frequency of two or more cycles per year for at least two years.
The relapse frequency for each patient was calculated for the pre­
lithium and lithium-treatment periods. After a six-an-a-half year 
treatment period, results indicated five patients to have had an 
increase in the frequency of cycles, six remained static arid seventy- 
seven showed a decrease of cycle-frequency. The mean pre-lithium 
relapse rate was calculated to be every eight months, and diminished 
to every eight-five months during the lithium period. The relapses 
that occurred during the latter period were of shorter duration and
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possibly of lesser intensity than during the pre-lithium periods.
For the group as a whole it was calculated that pre-lithium, the
patients spent an average of thirteen weeks per year in a psychotic
state and this diminished during the lithium period to less than two
weeks. Twenty-five patients discontinued their lithium medication
and relapses reappeared with the same frequency and duration as before
7 3
the lithium period ‘ .
7. 1.;
Angst, in 1970, in a co-operative open trial studied 114 bipolar, fifty- 
eight unipolar, and seventy-two schizoaffective subjects. The 224 
patients were selected for having had at least two cycles within the 
previous two years. The mean lithium treatment period favoured the 
bipolar group of whom seventy-six showed improvement. The duration 
of episodes was shortened and the intervals between cycles prolonged 
by sixty-one per cent. In patients suffering from unipolar depression 
and schizoaffective disorder the duration remained unchanged, but an 
interval prolongation was noted of seventy-six and thirty per cent 
respectively .
7.1.3
The same year Schou compared the relapse rate of patients during the 
lithium-period, the pre-lithium period, and after discontinuation of 
the drug. He demonstrated that the patients were as prone to relapse 
after lithium discontinuation as they had been before treatment started
7.1
7.1.4
Egli's 1971 open trial of ten bipolar, ten unipolar and twenty-five
schizoaffective patients, showed an improvement of the cycle frequency
in four, seven and sixteen subjects respectively. In this European
study the prophylaxis of unipolar illness thus appeared to be more
7 5
favourably influenced by the drug than the bipolar type ‘ .
S9.
7.1.5
In 1976, Prien and his associates analysed the results of a collabora­
tive study on the effectiveness of lithium prophylaxis in unipolar 
depressive disorder. Results from this study indicated that treat­
ment successes received a significantly higher lithium dosage than 
treatment failures. Fifty-five per cent of patients with levels of 
Q,7 m Eq/1 or less relapsed, compared with fourteen per cent of patients
with higher levels. No major difference in treatment outcome was
7 6
noted between patients with levels of 0,8 to 1,0 m Eq/1 or higher ' .
?. 1 .6
In 1982, Peselow and his associates, published their results of a trial 
to assess lithium's prophylactic effect in forty-three unipolar, 102 
bipolar, and sixty-nine cyclothymic patients. The probability of 
remaining free of one depressive episode after two years of lithium 
administration was calculated for each group. The probability 
percentage for bipolar patients was forty-two to fifty-five percent, 
thirty-one to forty-two percent for unipolar patients, and twenty-six 
to thirty-six percent for cyclothymic patients ^ .
7. 1.7
The American Psychiatric Association Task Force Report on Lithium Therapy 
published in 1975, concurred with the Neuropsychopharmacology Advisory 
Committee to the Food and Drug Administration's position that "Lithium 
is effective in preventing or diminishing" the intensity of recurrences 
of bipolar affective illness. It appeared to be effective also in
unipolar illness, but due to the small number of patients studied, there 
was still a need for further evaluation of prophylaxis in this condition
7.8
7.2 Controlled Studies
7.2. 1.
Fieve, in 1968, measured the antidepressant effect of lithium with that 
of imipramine in a placebo single-blind study. Lithium, imipramine 
and placebo were administered to thirty-six, ten and six patients respec­
tively. No alteration of frequency of attacks was produced by lithium.
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Relapses occurred in three lithium-treated, one imipramine-treated
and four placebo-treated subjects. The author concluded that some
bipolar patients experienced a mild prophylaxis of the depressed phase
7 9
while on lithium, albeit an insufficient one ‘ .
7.2.2
In 1970, Melia completed a double-blind discontinuation study with 
eighteen patients suffering from recurrent affective disorder. During 
the two year trial period five out of nine lithium-treated, and seven 
out of nine placebo-treated patients suffered relapses. The mean 
length of the relapse-free periods was 433 days for the lithium-treated 
and 224 days in the placebo-treated group. The author concluded that 
the difference between the two drugs was insignificant
7.2.3
Attempting to satisfy the criticisms which followed in the wake of his 
7 3
first study ‘ , Baastrup in 1970. conducted a double-blind comparison
of lithium and placebo. Patients who had been receiving lithium for
at least a year were crossed double-blind to either lithium or placebo,
and those who showed a decline of side effects were excluded. This
procedure had several advantages, e.g., firstly, the patients had been
on lithium therapy for a protraced period, and thus the trial could be
completed within five months. Secondly, the patients had already
passed the period of initial side effects, making it easier to preserve
the "blindness" of the trial. Thirdly, each patient already possessed
a known maintenance lithium dose. In the placebo-treated group the
twenty-two bipolars produced twelve relapses, i.e., fifty-five percent
within five months, and the seventeen unipolars produced nine relapses,
i.e., fifty-three percent. No relapses were encountered in the twenty-
eight bipolar and seventeen unipolar lithium-treated subjects. Those
patients who continued on lithium also continued relapse-free. The
author concluded that lithium was superior to placebo in "recurrent
depressive disorder" as well as in "recurrent manic-depressive disorder".
7 11
He also cautioned on the relapse risk when the drug was discontinued * .
71.
7.2. 4
In 1971, Coppen, in a co-operative study lasting 112 weeks compared
the prophylactic effect of lithium to placebo under double-blind 
7 12
conditions ' . The patients selected for the study had had
at least three cycles in three years, or three in the previous two years,
or two in the previous year. Serum lithium levels were maintained 
between 0,8 to 1,2 m Eq/1. Results revealed that the 1ithiurn-treated 
subjects experienced significantly less affective illness than the placebo- 
treated group, whether this was measured by time spent as an in-patient 
or by the duration of out-patient episodes. Of the thirty subjects 
receiving lithium, three out of sixteen bipolars and five out of twenty- 
seven unipolars relapsed. The thirty placebo-treated subjects 
exhibited relapses in twenty-one of twenty-two bipolar patients and 
eleven of fourteen unipolar patients. The amount of antidepressants 
or of antimanic medication prescribed was also significantly less in the
lithium-treated group. No patient in the 1 ithium-treated group
received EOT, whereas forty-three percent of the placebo-treated group 
received one or more courses of ECT. The author concluded that his 
results strongly supported those obtained by Baastrup and Schou
7.2. 5
Hullin, in 1972, conducted a double-blind trial over six months with
thirty-six patients of mixed affective states. He noted relapses
within the six-month trial period in one of the eighteen lithium-treated
7 18
patients and in six of the eighteen piacebo-treated subjects ' ‘.
7.2. 6
Gundall, in 1972, conducted a small double-blind study of twenty-four
bipolar and eight unipolar patients. Of the lithium-treated group
four of twelve bipolar, and three of four unipolar patients relapsed.
Of the piacebo-treated group, ten of twelve bipolar and two of four
7 5
unipolar patients relapsed ' .
72.
The focus of Stallone's report in 1973, was the investigation of
lithium prophylaxis in bipolar illness per se. Conducted under
double-blind, placebo-controlled conditions, this study consisted of
thirty-two patients suffering from bipolar affective disorder.
Lithium prophylaxis for periods upward of twenty-eight months was
assessed. Five of the nineteen lithium-treated and twenty-one
of the twenty-three piacebo-treated subjects suffered a relapse.
The conclusion of this prophylaxis study was that lithium prophylaxis
7 14
for bipolar mania was dramatic and unequivocal ’ .
7.2.7
7.2.8
In 1973, Prien and his associates, focused on the comparison of the 
prophylactic effects in recurrent affective illness of lithium and 
imipramine. Their double-blind study consisted of sixty-six subjects 
- twenty-four bipolar and twenty-three unipolar patients. Of these, 
fourteen bipolar and twenty-three unipolar patients were assigned to 
lithium while ten bipolar and nineteen unipolar patients received 
imipramine. Of the lithium-treated group five bipolar and thirteen 
unipolar patients relapsed, while eight bipolar and eight unipolar 
patients from the imipramine-treated group suffered a relapse.
Lithium therefore appeared the statistically better treatment in the 
prophylaxis of bipolar affective disorder. In unipolar patients
no significant difference between lithium and imipramine could be
. . . . .  7.15, 7.16
distinguished .
7.2.9
In another study by Prien and his associates, 205 patients diagnosed as 
manic-depressive illness, manic type, were treated either on lithium or 
on placebo for a two year period. The results from this trial coupled 
with those from other studies, indicated that lithium might be an effective 
treatment for preventing relapse in bipolar disorder
73.
To demonstrate the direct comparison of the prophylactic effect of 
lithium and maprotiline, Coppen, in 1976 performed a double-blind 
study of twenty-five subjects. The patients consisted of five 
bipolar and twenty unipolar patients. Four bipolar and twelve 
unipolar patients were allocated to lithium, while maprotiline was 
administered to one bipolar and eight unipolar patients for a period 
of one year. The serum lithium levels were maintained at its 
optimum concentration. The results of this study indicated that 
lithium might be a better treatment in bipolar states than maprotiline,
whereas in unipolar prophylaxis the two treatments were equally good
7 18
or lithium perhaps somewhat better ' .
7.2. 10
7.2.11
To assess the comparison of the prophylactic effects of lithium and 
mianserin, Coppen in 1978, conducted a double-blind study of forty-one 
patients. The subjects were selected for a history of at least three 
cycles of depression, then randomized to either lithium or mianserin 
for one year. No relapses occurred in the fifteen lithium-treated 
subjects, while seven of the thirteen mianserin-treated subjects suf­
fered a relapse. The metal proved infinitely superior to the tetra­
cyclic and the author concluded on the evidence that lithium was the
treatment of choice for the long-term prophylactic treatment of recurrent
7 19
affective illness - both unipolar and bipolar ‘ .
7.2.12
An analysis by Prien in 1979, of seven placebo-controlled trials 
involving over four hundred patients has demonstrated unequivocally
lithium's effectiveness in reducing the recurrence of bipolar affective
.. . 7.20
disorder .
7.2.13
An observation period of three years was chosen in a comparison of 
lithium and amitriptyline in the maintenance treatment of unipolar depres 
sion. Patients who had suffered from three or more episodes of depres
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sion were treated either with lithium or amitriptyline. The 
results after three years confirmed earlier findings that lithium
and TCA's are of equivalent efficacy in preventing relapse of unipolar
, . 7.21
depression .
7.2. 14
A placebo-controlled study by Coppen in 1981, has shown that where the
acute depressive phase is treated with ECT, maintenance with lithium
7 22
is more effective than placebo at one year in preventing relapse ' .
7.2.15
In a controlled study in 1982, Kane and his associates, compared the
prophylactic effects of imipramine, of lithium, of the combination
lithium-plus-imipramine, and placebo in twenty-seven unipolar and twenty-
two bipolar subjects. Their results suggest that lithium carbonate
. 7.23
might be effective also in the D r o o h y l a x i s  of unipolar illness .
7.2.16
To compare further the prophylactic qualities of imipramine and lithium, 
Prien in 1984, studied 117 bipolar and 150 unipolar patients. in this 
double-blind, long-term follow-up study the subjects were allocated to 
lithium or imipramine, or a combination of both, or to placebo.
Results indicated that with bipolar patients lithium equalled the 
imipramine-lithium combination and that both were superior prophylactic 
treatment to imipramine alone. With the unipolar group the combin­
ation lithium-imipramine equalled imipramine alone, while both treatments 
proved superior to either lithium or placebo alone ’ .
7.3 Conclusi on
From these studies it is clear that lithium acts as a prophylactic agent 
in bipolar disorder. There is also good evidence that it is effective 
in preventing unipolar relapses but in general the reports are less 
convincing than those obtained from trials on mania. The comparison 
of the prophylactic actions of lithium and the antidepressants is yet 
unestabli shed.
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7.4 Serum Lithium Levels with Maintenance Therapy
During maintenance therapy the intake of lithium must equal the
renal elimination to avoid toxicity. As the renal lithium
clearance varies among individuals and also decreases with advancing 
7 25
years ' , the optimum maintenance dosage also varies. Some
patients, particularly the young may require and tolerate a greater
dosage than the elderly. Individual adjustment of maintenance doses
is therefore essential. A serum lithium level of 0,6 to 1,2 m Eq/1
7 21
is advocated for maintenance levels between 0,4 to 0,6 m Eq/1 ' .
A multi-hospital co-operative study sponsored by the Veterans Adminis­
tration and the National Institute of Mental Health between 1968 and 
1972 found that serum lithium levels between 0,5 and 0,7 m Eq/1 
were ineffective in preventing relapses. Serum lithium levels
between 0,8 and 1,0 m Eq/1 were associated with a relatively low failure
7 6
rate ' . The general unanimity appears to recommend that levels do 
not exceed 1,5 m Eq/1 for fear of toxicity and considers levels below 
0,3 m Eq/1 as ineffective
7.5 Predicative Variables in Lithium Prophylaxis
Lithium maintenance treatment is indicated in patients who :
i)
ii)
have a familial predisposition to bipolar affective 
i11 ness;
have had at least two clearly distinct and characteristic
bipolar episodes, each lasting at least one month, and
. . 7 21
within two years at most ;
iii) treatment outcome may also be related to certain
7 24
characteristics of the index episode ' .
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7.6 The Duration of Prophylactic Treatment
Baastrup and his associates have discontinued lithium after treatment 
periods of one to seven years in a selected group of patients who had 
suffered few or no relapses during treatment. The subjects had 
experienced two or more manic or depressive episodes in the preceding 
two years before the initiation of the drug. After lithium dis­
continuation, more than half of the subjects experienced a relapse 
within six months. Patients who had been treated with lithium for
four to seven years had relapses with the same frequency as those
7 27
who had been treated for shorter periods of one to three years .
7 28
Ample evidence substantiates this fact ' . Indications are that
prophylactic treatment may thus require some prolonged, perhaps indeed, 
lifelong continuation of the drug. However, one may concede that 
subjects exist who may after a short prophylactic period be withdrawn 
from the drug without ill effects, but as yet this group has not been 
identified.
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CHAPTER 8
Lithium in Schizophrenia and Schizoaffective Illness
Following the findings that lithium is effective in the treatment 
of the manic phase of bipolar affective disorder, there have been 
numerous attempts to evaluate its effectiveness in a number of 
other psychiatric conditions, including schizophrenia and schizo­
affective disorders.
8.1 Lithium in the Treatment of Schizophrenia
8.1 . 1 Uncontrolled Trials
8.1.1.1
The use of lithium in the treatment of schizophrenia was first 
reported by Cade in 1949. He treated six patients with dementia 
praecox and noted that although no fundamental improvement was 
achieved, the patients became less excited and more amenable. On 
discontinuation of the drug the patients reverted to their previous
O 1
boisterous state u ' '.
8.1.1.2
Two years later, Noack also reported on the quietening effect lithium
O O
appeared to exert on excited schizophrenic behaviour u,<:.
8.1.1.3
Glesinger's uncontrolled study in 1954, showed lithium to improve not
only thirty-one of thirty-nine schizophrenics but also nine of twelve
8 2
hebephrenic patients ' . Yet, in 1958, M Schou noted in a review 
that lithium was without any sedative properties and therefore valueless
against schizophrenic agitation. He conceded however, that the drug
8 3
might benefit those patients with a marked affective overlay ‘ .
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8.1 .1 .4
In 1969, Gottfries grouped twenty-nine patients according to activity
levels into psychosis "schizo-affectiva" and "psychosis schizophrenia".
The latter consisted of ten subjects who had normal limb movements.
The results of the study indicated the "schizophrenia" group to have
8 4
remained unchanged after treatment with lithium ' .
8.1 .1 .5
Sikes, in 1970, reported on the effects of lithium in one undifferen­
tiated and three paranoid schizophrenic patients. No deterioration
was noted in any, while two of the paranoid subjects showed a good
, ,.,, . 8.2 
response to lithium .
8.1 .1.6
In 1980, Hirschowitz reported a study using a two-week trial of only 
lithium in thirty-one subjects. These patients met the DSM III 
and RD criteria for schizophrenia and schizoaffective disorders.
The group initially underwent a two-week washout period before 
receiving lithium for two weeks. The serum lithium levels were 
kept greater than 1,0 m Eq/1. Only one of nineteen patients showed 
significant improvement .
8.1 .1 .7
Zemlan, in 1984, reported a subgroup of schizophrenic-like patients who 
responded favourably within seven days of lithium treatment. The 
improvement was noted in the "core symptoms" of schizophrenia, i.e., 
hallucinations, delusions and formal thought disorder
8.1 .1.8
Reviewing the available literature in 1978, Miller commented on the 
diagnostic heterogeneity of the schizophrenic disorder, particularly 
of the schizoaffective condition. According to the author three 
trends were evident a propos the result obtained from lithium trials 
in schizophrenia :
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i) a general effectiveness of lithium in both affective 
and schizophrenic symptomatology,
ii) a general ineffectiveness in both these states,
iii) a selective value in only affective symptomatology
8.7
8.1.2 Controlled Trials
8 . 1. 2.1
In 1968, Rimon studied thirty patients in a "state of confusion". 
These patients would probably be diagnosed as schizophrenic according 
to DSM III. Lithium was administered for a rather short period 
of seven days and compared to the effects of chlorpromazine.
Results indicated the superiority of the neuroleptic. The author 
concluded that in schizophrenics without a major affective component,
O O
lithium seemed valueless °’u .
8.1 .2.2
In 1971, Shopsin published the first controlled study of the comparison 
of the efficacy in schizophrenia of chlorpromazine and lithium.
This double-blind study involved twenty-one schizophrenic patients 
of mixed subtypes, e.g., nine undifferentiated, eight paranoid, and 
three excited schizophrenic subjects. The patients were randomized 
to either chlorpromazine or lithium, and regularly rated on six 
different scales. Results indicated that chlorpromazine enjoyed a 
non-statistical superiority over lithium. Lithium was considered
detrimental to six of the eleven lithium-treated subjects
8.9
8.1.2.3
In 1975, Small reported the results of a double-blind, placebo-controlled 
study of twenty-two schizophrenic patients. Apart from seven schizo­
affective patients, the group included five catatonic, two paranoid and 
six hebephrenic patients, all of whom had failed to respond satisfactorily 
to various other treatment approaches. Of the schizophrenic group 
six showed significant improvement on lithium. The author concluded 
that a trial of lithium combined with a neuroleptic might be warranted
O IQ
in neuroleptic-refractory patients .
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8.1.2.4
Taheri, in 1976, reported on four schizophrenic patients who improved 
on lithium. No diagnostic criteria or treatment details were 
supplied .
8.1 .2.5
In 1979, Alexander documented a double-blind study comparing the 
effect on schizophrenic symptomatology of lithium and placebo.
Five patients diagnosed in accordance with Research Diagnostic Criteria 
(RDC) were allocated to placebo for one week followed by lithium for 
three weeks and finally placebo for two weeks. Two of the subjects 
showed a good response, one of whom relapsed within two weeks of 
lithium withdrawal, while three remained stable. The author con­
cluded that lithium had anti-psychotic as well as anti-manic and anti­
depressant properties
8 . 1 .2.6
Growe, in 1979, published a placebo-controlled, double-blind study 
of six schizophrenic and twenty-eight schizoaffective subjects. All 
thirty-four patients were diagnosed in accordance with RDC. Neuro­
leptic medication was maintained at constant dosage throughout the 
trial. Serum lithium levels were maintained between 0,5 to 1 , 0 m  Eq/1
O -10
Results indicated that lithium was superior to placebo U ' IJ.
8.1 .2 .7 Cone!usion
The results from these trials are clearly conflicting and by no means 
approximate those obtained from lithium studies in mania. The 
studies are obviously hampered by the unspecificity of diagnostic 
criteria, the lack of control groups and the small number of participants
8.2 Lithium in the Treatment of Schizoaffective Disorder
8.2.1 Uncontrolled Studies
8.2 .1.1
From his 1968 study, Zall concluded that lithium was effective in
controlling the affective component of schizoaffective disorder.
O 1/
but had no therapeutic action on the schizophrenic component u ’'
8.2 .1.2
The following year, Serry published the results of a lithium trial in 
eleven schizoaffective patients. Six of these patients were lithium- 
retainers. Although he stated that one lithium-excreting schizo­
affective patient showed no response to lithium, he omitted to state 
the outcome of treatment of the remaining four patients
O O 
U  . L.
8.2.1.3
In 1969, Gottfries conducted an open study with diagnostic criteria
based among others on physical activity. Nineteen schizoaffective
patients with a disturbed activity level were treated with lithium.
The drug appeared to normalize this level. The author concluded
that psychotic patients with a disturbed activity level benefited
8 4
from lithium therapy ' .
8.2.1.4
In an uncontrolled and collaborative trial Angst, in 1970 studied 
seventy-two patients to determine the prophylactic value of lithium 
in schizoaffective disorder. The subjects were diagnosed in 
accordance with World Health Organization Criteria. Their course 
of illness was compared for the lithium-treated period and for an 
equal period preceding initiation of lithium. Serum lithium levels 
were maintained between 0,8 to 1,2 m Eq/1. The drug led to a sig­
nificant reduction in the number of both hospitalizations and psychotic 
episodes in thirty-five percent of the patients. Twenty-five patients, 
i.e., thirty-five percent, remained unchanged, while twelve patients, 
i.e., sixteen percent, relapsed with increased frequency. The 
affective cycles were also prolonged by thirty percent. The author 
concluded that the prophylactic value of lithium in schizoaffective 
illness compared favourably to its prophylactive effect in bipolar 
affective disorder
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8.2.1.5
In 1974, Smulevitch reported a study of lithium prophylaxis in forty- 
nine successfully treated patients. the author concluded that the 
drug was an effective prophylactic agent in both affective and schizo­
phrenic features of the illness
8.2.1.6
A study by Hirschowitz in 1980, consisted of thirty-one patients 
meeting DSM H I  and R D criteria for schizophrenia. Seventy-eight 
percent of the responders, i.e., seven of nine patients met DSM III 
criteria for a schizophreniform psychosis. The author concluded that 
patients with an affective component to their illness showed a better 
response to lithium than patients who distributed themselves along the 
schizophrenic continuum of this illness
8. 2.2 Controlled Studies
8 .2 .2.1
In 1971, Johnson compared the efficacy of chlorpromazine to lithium in 
eleven "schizoaffective" patients. His criteria for patient selection 
included :
i) no definite basic personality type, excluding schizoid 
dysfunction,
ii) insidious onset before twenty-five years of age,
iii) illness leading to residual personality disorganisation,
iv) purposeless behaviour and posturing.
One may question these criteria, especially the disorganisation of 
personality, which rather indicates a schizophrenic process. Five 
excited schizoaffective patients received lithium, while six patients 
were allocated to chlorpromazine. During the twelve-day study period 
the serum lithium levels were maintained at levels greater than 1,0 m Eq/1 
Of the eleven subjects six deteriorated, four remained unchanged and one 
recovered. The author concluded that lithium had virtually no thera­
peutic effect in excited schizoaffective patients and appeared to be an
8 18
inferior treatment to chlorpromazine ' . These results were opposed
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by Egli in 1971 He treated twenty-five schizoaffective patients
with lithium. Sixteen improved, six remained stable and only three 
deteriorated
8.2.2.2
In a multihospital collaborative trial eighty-three schizoaffective 
patients were studied to determine the efficacy of chlorpromazine and 
lithium in this disorder. The subjects were classified as highly 
or midly active and then randomized to either lithium or chiorpromazine 
for a period of three weeks. In the highly active group of forty- 
two patients, twenty-five received chlorpromazine and seventeen received 
lithium. Of the 1ithium-treated group, eight discontinued due to poor 
response. Of the forty-one mildly active subjects, twenty-one 
received chlorpromazine and twenty were allocated to lithium. Serum 
lithium levels ranged from 0,6 to 2,0 mEq/1. In the highly active 
group chlorpromazine was significantly superior to lithium, while in
the mildly active group the author could discern no difference between
.. . , 8.20
the two drugs .
8.2.2.3
A double-blind, placebo-controlled study of seven schizoaffective patients 
conducted by Small in 1975, demonstrated that all three of the excited 
schizoaffective group were lithium responders. Only one of the four
Q  ^Q
depressed schizoaffective patients responded while none deteriorated ‘ .
8.2.2.4
In 1978, Brockington reported on two drug trials. Sixty-eight patients 
were classified as either schizomanic or as schizodepressive. The 
nineteen schizomanic subjects were treated for one month on a double-blind 
basis with chlorpromazine or lithium. The forty-one schizodepressive 
patients were treated with amitriptyline and/or chlorpromazine. In 
the schizomanic group lithium seemed as effective as chiorpromazine,
while in the schizodepressive group chlorpromazine appeared the better
, 8.21
drug .
8 4 .
8.2 .2 .5
In 1979, Biederman reported on the combined use of lithium and halo- 
peridol in schizoaffective disorder. Schizophrenic schizoaffective 
patients showed considerably less improvement during the course of 
lithium therapy than the affective schizoaffective patients. However, 
the lithium-haloperidol combination appeared as effective for the 
affective schizoaffective patients as for the schizophrenic schizo- 
affectives. The author also cautioned against this drug combination 
for fear of neurotoxicity
8.2 .2.6
In 1979, Alexander documented a double-blind study comparing the effects 
of lithium and placebo on schizoaffective disorder. Eleven patients 
diagnosed in accordance with RDC were allocated to placebo for one week, 
then received lithium for three weeks and another two weeks on placebo. 
All three manic type schizoaffective patients improved, while two of the 
five depressed schizoaffective patients responded. One of these
relapsed when lithium was withdrawn
8.2.2 .7
Brewerton, in 1983, double-blindly studied the effects of lithium and/or
L-tryptophan in seven schizoaffective patients. He demonstrated a
8 23
possible lithium potentiating effect by L-tryptophan ' .
8.2.2.8
Reviewing the available literature in 1979, Prien commented on the 
scarcity of controlled trials comparing lithium with neuroleptic drugs, 
and on the contradictory findings demonstrated by several of the trials. 
According to the author three trends were evident from the results 
obtained from the studies.
i) a general effectiveness of lithium in both the affective 
and schizophrenic components of schizoaffective disorder.
ii) a selective effectiveness in only the affective component 
of the illness
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iii) a general ineffectiveness
The author also noted that lithium might be beneficial
, . .. .. 8.24
schizoaffective recurrences .
in preventing
8.2.2.9 Conclusion
In summary, it becomes apparent from the trials, that for the most 
part either the diagnosis was not clearly specified or the study was 
not double-blind, therefore rendering the results uncertain. Despite 
these factors many trials appear to tender positive results pointing 
to lithium's usefulness in mildly active schizoaffective illness.
The prevailing opinion appears to be that the more predominant the 
affective component the more effective the lithium therapy. Other 
predicative features include also a history of manic attacks and a 
family history of bipolar illness.
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CHAPTER 9
Lithium in the Treatment of Eating Disorders
A relationship between depression and anorexia has been postulated
with the suggestion that antidepressant remedies might merit further
9 1
exploration in the management of this disorder ‘ . It is therefore
9 2
not surprising that lithium, with a propensity to induce weight gain , 
has been tested in the treatment of this dysfunction.
9. 1 Anorexia Nervosa
The use of lithium in anorexia nervosa has been reported in three trials.
9.1.1 .
In 1977, Barcai reported on two adult patients suffering from anorexia.
The first case was a twenty-nine year old woman with a fourteen year
history of anorexia. She had on occasion displayed pressure of
speech, hyperactivity and unstable mood, which the researcher interpreted
as manic-like symptoms. Impramine had been administered to treat
depressive bouts and chiorpromazine to treat the over-excited phases.
When lithium was substituted for these drugs an improvement of mood was
noted at a serum lithium level of 0,9 m Eq/1. Weight gain amounted
to twelve kilogrammes (kg) over twelve weeks. The second case was a
forty-four year old woman with a twenty year history of the illness.
Her weight oscillated in a cyclical fashion and appeared linked to
emotional stresses. A history of affective disorder in a first
degree relative was present. The patient had on one occasion
developed post-natal depression which cleared with ECT, although her
weight remained low. After lithium administration to attain a serum
9 3
level of 0,95 m Eq/1 the patient gained ten kq within six weeks ’ .
One may question the severity of the disorder in the second case as 
amenorrhoea was absent.
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9. 1.2
Gross, in 1981 reported a double-blind, placebo-controlled trial of 
lithium in sixteen patients with anorexia nervosa. The patients 
were amenorrhoeic, had lost at least twenty per cent of their body 
weight, and were more than fifteen per cent below their ideal body 
wei ght.
The subjects had a distorted attitude towards food with denial of
nutritional needs. Lanugo, bradycardia,periods of overactivity,
and induced vomiting were present. All were hospitalized and
received behaviour modification therapy. The lithium treated group
achieved a mean serum level of 1,0 m Eq/1 over the four week study.
Significant differences in weight gain between the two groups favouring
the lithium therapy was evident at weeks three and four. The author
also cautioned about the dangers of using lithium in these patients
who are known to severely restrict intake, self-induce vomiting and
9 4
abuse laxatives and/or diuretics ' .
9.1.3
In 1982, Stein reported the utility of lithium therapy in an intractable 
anorexia patient with hypomanic-1ike mood swings. Anorexia was present 
since the age of eleven years. Depressive thought content was evident 
at the age of fifteen years. Behaviour regimes for feeding, individual 
and family psychoterapy, four TCA's, chlorpromazine and thioridazine were 
unsuccessfully tried in succession. At the age of sixteen years, 
lithium was started and at a blood level of 1.0 m Eq/1, an immediate 
change in mood and in general behaviour was evident. Gradually her 
weight rose from twenty-five kg. to forty-four kg. She grew in
stature and menses appeared at the age of eighteen years. A follow-up
9 5
period of one year demonstrated a stable condition ‘ .
9.1.4 Conclusion
It is questionable whether lighium influences anorexia nervosa at a 
primary level. The drug more likely ameliorates the affective com­
ponent in a selected group of anorexic patients, thus enabling them to 
become more responsive to psychotherapeutic measures.
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9.2 Buiimia
. . .  9 6
The successful treatment with lmipramme of this disorder ’ , has 
resulted in a single trial of lithium in bulimia.
9.2.1. .
Hau, in 1984 reported a study of fourteen bulimic patients treated 
with lithium. The subjects fulfilled DSM iii criteria for bulima 
without concurrent anorexia nervosa, although ten patients had a 
previous history thereof. Eight patients were treated with a 
combination of lithium and behaviour therapy. Serum lithium levels 
were maintained for at least four weeks between 0,6 and 1.2 m Eq/1.
Six patients were treated with behaviour therapy and crossed to lithium
only after relapsing or responding poorly to behaviour therapy.
After a period of eight weeks, six of the eight patients on lithium
showed marked and two showed moderate improvment. Two patients
were given lithium after unsatisfactory improvement with behaviour
therapy. One patient improved markedly and the other showed only
moderate improvement. Of four patients who were given lithium after
relapsing, two showed a marked improvement and two remained unchanged.
The frequency of bulimic episodes was generally reduced by seventy-five
to hundred per cent. The author concluded that the possible action
9 7
of lithium in this disorder might be its antidepressant action ' .
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CHAPTER 10
Lithium in the Treatment of Substance Use Disorders
Several researchers have assumed that disorders such as alcoholism, 
drug dependence and antisocial acts are in reality clincial manifes­
tations of underlying affective disorder. They have maintained that 
appropriate treatment of the affective component should result in 
improvement of the secondary symptomatology
10.1 Lithium in the Treatment of Alcoholism
Animal studies have indicated that lithium reduces alcohol consumption
in alcohol dependent rodents, but no such clinical interaction could be
10 2
demonstrated in humans ‘ . When dipsomania results from a masked
depressive illness it has been suggested that lithium could be of
10 3
prophylactic value ‘ . It has also been postulated that the drug
directly decreases the desire to imbibe alcohol, possibly by reducing
, . . . 10.4
hypomamc periods .
10.2 Lithium Trials in Alcoholism
10 . 2.1
Kline, in 1974, in a double-blind, controlled study, studied the use 
of lithium in treating alcoholic patients. The trial lasted two years. 
Seventy-three detoxified chronic alcoholics were selected. All 
subjects suffered from nonpsychotic depression. All medication was 
discontinued for one month prior to lithium treatment to prevent 
contamination of the results. Lithium was adjusted in the subjects 
of the lithium group to maintain a serum level of 0,6 to 1,2 m Eq/1.
Over the two year period significantly fewer drinking episodes were 
reported for the lithium group when compared to the placebo group.
Over a period of one year, relapses occurred in nine of fourteen placebo 
treated patients and in four of sixteen lithium treaced subjects.
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The author concluded that lithium appeared to have a statistically
significant effect on the chronic dipsomanic. Hy hypothesized
that lithium might primarily benefit the illness or perhaps have a
10 5
direct effect upon the neurotoxicity associated with alcoholism ' ,
10. 2.2
A second double-blind, placebo-controlled study to assess the pro­
phylactic use of lithium in the treatment of dipsomanics was conducted 
by Merry in 1976. In this year-long investigation seventy-one 
patients were classified as alcoholic. After detoxification and whilst 
all medication was discontinued the subjects were categorized as de­
pressed or non-depressed. Patients were then randomized to either 
lithium or placebo. Lithium serum concentration was maintained at 
levels of 0,8 to 1.2 m Eq/1. Forty-six per cent of the patients
failed to complete the study. Results indicated that drinking morbidity 
was higher in depressed as compared to non-depressed patients.
Lithium reduced the number of days incapacitated by alcohol in the 
depressed group. No significant effect on alcohol consumption on 
a daily basis was noted between the two groups. The author concluded 
that lithium induced a significant improvement in alcoholic symptomatology 
in depressed dipsomanics
10.2.3
In 1977, Young treated fifteen patients with bipolar affective disorder 
and alcoholism. Improvement was noted in eight subjects for at least 
six months, and freedom from alcoholism in five patients. A greater 
morbidity from alcoholism than from affective disorder was found. 
Relapses occurred equally in both conditions for all patients after 
twelve months of lithium treatment
10.2.4
Judd, in 1977, using non-addicts in a cross-over double-blind study 
found no difference in alcohol induced "highs" after two weeks of 
lithium or placebo treatment
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10.2.5,
According to Boland in 1978, lithium might be the preferred treatment for
the bipolar dipsomanic. He reported that thirty-six per cent of
patients abstained from alcohol for as long as six months after lithium
discontinuation. This compared favourably with the twelve per cent
10 9
abstinence for similar but non-lithium-treated patients ' .
1 0 . 2 . 6 ,
In 1981, McMillan reviewed the available lithium studies in alcoholism. 
He suggested that lithium might act directly on intoxication effects
by reducing general drug euphoria, and not simply by alleviation of the
_  .. . 10.10
affective component .
10.2.7,
This theory was corroborated by Himmilhoch in 1983. 
trial of lithium led to decreased intake of alcohol 
thirty-nine dipsomanics. The author assumed the 
to be biological .
His short-term 
in twenty-six of 
effect of lithium
10 . 2.8
Fawcett, in 1984, conducted a piacebo-control 1 es study of eighty-four 
dipsomanics. The subjects were randomized to either a lithium or 
placebo treatment group for eighteen months. Of the lithium-treated 
group eighty-seven per cent were abstinent after six months and fifty 
per cent after eighteen months. Of the placebo-treated group fifty- 
two per cent were abstinent after six months and thirty-eight oer cent 
after eighteen months. Results of this trial did not substantiate 
the positive predicative value of the state of employment or of the marital 
status but implicated the therapeutic serum lithium level and medication 
compliance as indices of treatment outcome "  ".
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10.2.9 Cone!usion
In summary, the studies suggest that lithium is superior to placebo and 
appears to confer some slight benefit on the drinking behaviour and 
particularly on mood in dipsomanics with concurrent affective disorder.
10. 3 Cocaine
Observations™ uncontrolled studies have indicated that lithium 
attenuated the euphoriant effects of cocaine A subsequent
study however, reports lithium to be of value only in the depressed 
cocaine abuser
10. 4 Marijuana
Marijuana has been reported to increase the serum lithium level
10.2
Lithium has also been demonstrated to attenuate the subjective effects 
of marijuana These reports however, are anecdotal and
unsubstantiated.
10. 5 Hal 1ucinogens
Horowitz has described a subgroup of individuals who were predisposed 
to primary affective disorder and who experienced manic symptoms 
following the ingestion of lysergic acid diethylamide. He demonstrated 
that these patients were particularly responsive to lithium treatment
93.
10 ..6 Amphetami ne
Several studies have suggested that lithium pretreatment reduced 
amphetamine-induced activation and euphoria The studies
still require substantiation.
10. 7 Opiates
Anecdotal reports have indicated that lithium may block the euphoric 
effects of opiates and alleviate withdrawal symptoms. However, results 
are hampered by poor co-operation and a high dropout rate /\
double-blind, placebo-controlled study by Jasinski indicated that lithium 
did not block the euphoric effects of morphine
10.8. Concl usion
It is clear from the results of these trials that lithium has no 
established role in the treatment of primary substance abuse.
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CHAPTER 11
Lithium In the Treatment of the Premenstrual Syndrome
Because of its obvious affective component and inherent periodicity 
it is not surprising that lithium would also be applied in this syndrome.
11 . 1 Lithium Studies in Premenstrual Syndrome
11. 1.1
Sletten, in 1966, reported on eight patients suffering from premenstrual 
syndrome (PMS). All subjects were refractory to various other treat­
ments including anxiolytics, diuretics and psychotherapy. The treatment 
regime consisted of lithium carbonate 900 mg/d. for eight days prior to 
the expected start of the menses and to discontinue the drug at the onset 
of flow. Treatment continued in this fashion for twelve to eighteen 
months. Results demonstrated that all eight subjects responded 
favourably
11 . 1.2
Fries, in 1971, reported that two of five patients suffering from PMS
11 2
benefitted from lithium ' .
11.1.3
Singer, in 1974, compared lithium with placebo in a double-blind, cross­
over study involving nineteen patients suffering from PMS. Twelve 
of the subjects were diagnosed as having concomitant, other psychiatric
ailments. Both the lithium and placebo-treated groups improved and
11 3
no significant differences between the treatments could be detected ‘ .
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11.1.4
Steiner, in 1980, studied fifteen patients with severe PMS. This
study lasted for a period of three months. All patients received
lithium to maintain serum levels of 0,3 to 0,85 m Eq/1. Results
indicated five patients to have deteriorated. Three women clearly
benefitted from the treatment but appeared also to have had cyclothymic
features. Two of these subjects had first degree relatives with
diaqnosed affective illness. The author concluded that lithium was
11 4
not recommended for the average woman with PMS ‘ .
11.2 Conclusion
In summary, it appears that only women with an affective component to 
PMS are likely to respond favourably to prophylactic lithium treatment. 
The lack of double-blind and placebo-controlled studies should caution 
the use of lithium in even the woman with an affective overlay to her 
premenstrual tension.
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CHAPTER 12
Lithium In the Treatment of Personality Disorders
As early as the 1960's Giesler and Baastrup presented case reports suggesting 
that lithium might be useful in a broad spectrum of psychiatric disorders. 
Subsequently there appeared reports of lithium use in many illnesses including 
the broad spectrum of personality disorders.
12.1 The Personality Dysfunction without an Affective Component
12.1.1 Obsessive Compulsive Personality Disorder
The first study to test the efficacy of lithium in the treatment of obsessive-
compulsive personality disorder was conducted by Giesler in 1969. This
double-blind study consisted of six patients diagnosed as obsessive-compulsive.
A cross-over design with placebo was incorporated into the trial. Lithium
levels were maintained from 0.6 to 1.4 m Eq/1. Results demonstrated that
four subjects remained unchanged and two improved gradually over a period of
two to four months. This improvement was considered to be an effect of
time, as it did not relate to a period of medication. The author concluded
12 1
that lithium was valueless in the treatment of obsessive-compulsive disorder
In the same year Baastrup commented that some patients with the disorder
12 2
"sometimes" respond to lithium ‘ . Forssman also reported some cases
12 3
of obsessive-compulsive dysfunction who apparently improved on lithium ‘ .
. 12 4
Five patients not benefiting from the drug were documented by Gottfries ' .
A recent report by Stern documented the case of a single obsessive-compulsive
12 5
patient successfully treated with lithium ‘ .
12.1.2 Anxious Personality Dysfunction
In an attempt to demonstrate some anti-anxiety effect of lithium, Lackroy 
in 1971, treated thirty-five normal individuals with the drug. Twenty-five 
patients received lithium, and ten received placebo. Three dosages of 
600 mg lithium were administered within twenty-four hours. Anxiety ratings 
were repeated twenty-four hours later just prior to myelography.
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Results indicated the lithium-treated group to experience the same amount
of anxiety as the placebo-treated group. The authors concluded that
12 6
lithium exerted no measurable influence on acute anxiety ‘ .
12.2 The Personality Dysfunction with an Affective or
Aggressive Component
12.2.1 Cyclothymic Personality Dysfunction
Blinder, in 1968, treated twenty-two hypomanic patients with lithium and
12 7
reported a success rate of ninety-five percent ' . In 1969, Baastrup
reported lithium's mood stabilizing action in patients with cyclothymic
personality thus supporting Dyson's study of the previous year
In the latter study, all of ten cyclothymic patients of a 1ithiurn-treated
group showed a favourable response to the drug. Dunner, noted in 1976
that one of four cyclothymic patients receiving lithium had a depressive
relapse over an average of fourteen months. A similar relapse rate over
a similar period was found in two of four cyclothymic patients receiving a
placebo Peselow estimated the probability of remaining free of
one depressive episode after two years of taking lithium to range from
twenty-six to thirty-six per cent for cyclothymic patients. The mean
probability percentage for bipolar and unipolar illness was estimated at
12 11
forty-nine and thirty-seven per cent respectively * .
12.2.2 Dysthymic Personality Dysfunctions
Fries found lithium of no value in the treatment of eight neurotic
12 12
patients who had no endogeneous features to their illness • .
been substantiated by several other researchers ^.13^
depressive 
This has
12.2.3 Lithium Studies in Aggressive Personality
12.2.3.1
The efficacy of lithium in the control of violence and aggression was tested 
by Tupin in 1971. Twenty-five prisoners with violent behaviour and 
occasional self-mutilation served as subjects. All subjects were refrac­
tory to other treatment measures, including phenothiazines, anticonvulsants 
and ECT. Lithium was administered for three months effecting serum levels
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0.6 to 1.0 m Eq/1. Results indicated that thirty-six per cent of the
prisoners had an excellent and forty per cent a good response in the lowering
12 9
of aggression rating scales ' .
12.2.3.2
Sheard in 1971, conducted a single-blind study of lithium and placebo on
twelve male prisoners. Criteria for selection included a history of
violent, assaultive crimes, aggressive behaviour in prison, no psychotic
features present, high scores on aggression items of MMPI, and an Intelligence
Quotient over eighty-five. Placebo and lithium were administered for four
week periods in an alternating sequence for a total period of three months.
Serum lithium levels were maintained between 0.6 m Eq/1 and 1.5 m Eq/1.
Results indicated a significant reduction in aggressive affect in the lithium
treated group as compared with the placebo-treated group. This phenomenon
12 14
the author attributed to the effect of lithium on the serotoninergic system ’
12.2.3.3
In 1972, Rifkin conducted a double-blind, controlled study of twenty-one 
patients with emotionally unstable character disorder. This label was 
attached to patients who displaced chronic maladaptive behaviour patterns and 
having at its core specific and resistant mood swings. The subjects were 
randomized to either lithium or a placebo for a period of six weeks.
This was followed by a cross-over to the other drug. Serum lithium levels 
were maintained from 0.8 to 1.5 m Eq/1. Results indicated that the lithium- 
treated group fared better than the placebo-treated group. The author
postulated that the improvement was due to lithium dampening the affective
,, , 12.15
fluctuation .
12.2.3.4
In 1973, Cooper published a study demonstrating the favourable effect of 
lithium in a young mentally retarded female with hyperactivity and severe 
self-mutilation. The subject being refractory to other treatment measures 
received lithium as a final resort. She improved dramatically within one 
week at a serum lithium level of 0.9 m Eq/1. The subject remained well on 
lithium over the ensuing five-year follow-up period
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12.2.3.5
Micev, in 1974 conducted an open trial with ten severely mentally retarded
patients who all displayed aggressive and self-mutilating behaviour.
All ten subjects were refractory to various other treatment procedures.
Lithium was administered to obtain serum levels ranging between 0.6 to
1.4 m Eq/1. Fifty per cent of the subject sample improved significantly
according to aggression rating scales. Six of eight patients with self-
mutilating tendencies improved to a point where the self-mutilation ceased.
The authors assessed lithium to be therapeutic in aggressive states and
12 17
particularly in patients whose main problem was self-mutilation ' .
12.2.3.6
A double-blind study to evaluate the effect of lithium on aggressive 
behaviour was conducted by Sheard in 1975. Sixty-six prisoners between 
the ages of sixteen to twenty-four years served as subjects. The selection 
criteria included :
i)
ii)
a conviction for serious aggressive crimes, and 
a nonpsychotic state
Lithium was administered to maintain a serum lithium level in the range of 
0.6 to 1.0 m Eq/1. Administration of the drug continued for a period of 
three months, and was preceded and followed by a one month drug-free period. 
A progressive decline in aggression ratings was noted month-to-month, 
eventually reaching zero by the fourth month in the lithium-treated group.
A tendency towards recurrence of previous aggressive behaviour was noted 
during the second lithium-free placebo period. The author noted also a 
greater anti-aggressive effect of lithium with serum lithium concentrations 
higher than 0.6 m Eq/1. than below this level. He concluded that the 
drug had an inhibitory effect on impulsive aggressive behaviour
12.2.3.7
In 1977, Goetz! reported on three adult patients who displayed hyperactive 
and hostile behaviour. All three subjects were mentally handicapped and 
appeared refractory to other treatments. After administration of lithium, 
all three subjects showed improvement at serum levels of 0.7 to 0.9 m Eq/1.
1 0 0 .
Due to side effects, lithium was discontinued in the third subject
with subsequent relapse. The author assumed the anti-aggressive
mechanism of lithium as either a direct and specific effect, or by improving
an underlying manic depressive illness. He also noted that improvement
of aggression coincided with the serum lithium concentration reaching
12 19
0.7 to 0.9 m Eq/1 .
12.2.3.8
Fifteen aggressive mentally retarded patients were the subjects of Dale's 
study in 1980. Rating scores were vested in the percentage of aggression- 
free days over three periods of time. Period 1 was drug-free, while 
periods 11 and 111 were lithium-treatment periods. Lithium was adminis­
tered to maintain a serum lithium level of 0.4 to 1.2 m Eq/1. Improved 
rating scales were noted in eleven of the fifteen subjects. Three patients
remained unchanged and one patient deteriorated. Improvement was usually
12 20
evident within one or two weeks * .
12.3 Lithium in the Treatment of Sexual Disorders
The use of lithium in these dysfunctions is anecdotally documented. Some
12 22
observations have indicated positive effects in pathological hypersexuality '
12 23
Ward, in 1975, successfully treated a patient with transvestism ' .
The patient, however, suffered also from bipolar affective disorder with 
manic episodes which coincided with cross-dressing behaviour. It is 
questionable whether lithium therapy directly improved the secondary particular 
manifestations of mania, i.e., transvestitism in this subject.
12.4 Conclusion
The results from these trials are fairly consistent and indicate that lithium 
produces some anti-aggressive effect, particularly in retardates. Research
has indicated that lithium induces feeling of withdrawal from interpersonal
12 8 ^
and environmental demands * . This may provide a possible explanation for 
its action in reducing aggression. Some benefit is also obtained from the 
drug by cyclothymic patients. However, trials are mainly uncontrolled and 
consist of few subjects. Further research into these conditions is 
considered imperative.
CHAPTER 13
The Use of Lithium in Organic Brain Syndrome
Both Shopsin and Schou advised against the use of lithium in Organic Brain 
13 1 1 3 ?
Syndrome (OBS) "  ’ " . Despite these warnings and the assumed pro­
pensity of lithium to cause neurotoxicity with or without the addition of 
neuroleptics "l3‘3, 13,4, 13-5, the drUg has been administered in OBS.
13.1
Horowitz in 1975, reported the efficacy of lithium in four patients following 
the ingestion of LSD. The hallucinogen had apparently unmasked an under­
lying manic-depressive illness. All four subjects responded to lithium
. . 13.6
treatment, two after an unsuccessful trial of phenothiazines ' .
13.2
In the same year, Rosenbaum published a case report of a fifty-seven year
old male, who after resection of the right temporal lobe developed hypomania.
Hallucinations were prominent and seizures also appeared. With the adminis
1 3 7
tration of lithium the manic symptomatology ceased ' .
13.3
In 1977, Young documented a study of three OBS patients with concomitant 
bipolar affective disorder - manic episode. In the first subject lithium
alleviated the manic symptomatology without influencing brain dysfunction. 
There was some evidence from case three that lithium might even have had a 
beneficial effect on the patient's organic cerebral dysfunction. In all 
three cases, follow-up a year later showed lithium maintenance to have 
provided symptomatic relief without adversely affecting the associated OBS "*w,‘
13.4
Falk demonstrated in 1979 that the psychiatric morbidity among forty-four 
multiple sclerosis patients treated with adrenocorticotrophic hormone (ACTH) 
might be in the region of eighteen per cent. In a comparison group of
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twenty-seven patients treated concurrently with ACTH and lithium as a
prophylactic agent, no psychotic reactions or mood disorders of even
moderate intensity were noted. The author concluded that lithium might
benefit the steroid-induced psychosis, particularly in patients who previously
13 9
have had recurrent induced episodes ' .
13.5
The cognitive and affective responses to lithium were evaluated by Williams 
in 1979. Ten subjects with OBS were treated with lithium. Six 
improved dramatically, particularly in memory and speech. The author 
emphasized that these subjects were substantially demented, who in most 
cases were unable to care for themselves before lithium treatment.
Three subjects were subsequently discharged
13.6
Oyewumi, in 1981 reported a case of an adolescent developing cyclothymic
symptoms eight years after cerebral surgery. The patient responded to
lithium only at levels required to abort acute manic attacks. Below
13 11
lithium levels of 0.4 m Eq/1. the subject would relapse ’ .
13.7
In 1982, Hale reported on five OBS patients. Three of these had experienced
major head trauma, one presented with dolichoectasia (abnormal dilation of
cerebral vessels) and one had a steroid-induced psychosis. Lithium adminis-
stration resulted in favourable responses in all five subjects, each of whom
possessed some typical feature of bipolar affective disorder. The author
cautioned against lithium intoxication developing, particularly in OBS
13 12
patients within the normal therapeutic range ' .
13.8 Conclusion
Although lithium itself has been implicated in subclinical EEG abnormalities 
and may contribute directly to organic brain syndromes, the results of these 
trials tend to indicate that lithium may be a safe treatment for affective 
disorders in OBS. A paucity of studies and research however, still exists 
in this direction preventing a formulation of a definite opinion.
1C 3.
CHAPTER 14
Lithium and Psychiatry
The Use of Lithium in the Young and the Elderly
Despite the tendency of lithium to accumulate in immature bone, its pro­
pensity to stimulate growth hormone, and its assumed adverse effect on 
memory, the drug has been uti1 ized in the treatment of certain disorders 
of the growing child.
14.1 The Use of Lithium in Childhood Disorders
14.1.1 Aggressive States in Children
The successes enjoyed by lithium in the treatment of aggressive behaviour
14 1 14 2 14 3
have been reported from lithium trials on adults ' ’ ' ’ ' .
Sheard's study of aggressive adolescent prisoners had already demonstrated 
the efficacy of lithium in this condition. Lena reported in 1975 the 
study of a nine year old boy with severe intractable aggressive behaviour. 
The subject was considered refractory to various other treatments.
14 4
The administration of lithium normalized the child's behaviour ‘ .
14.1.2 Bipolar Disorder in Children
Diagnostic heterogeneity, the assumed rarity of bipolar illness in the young, 
and the osychotherapeuticemphasis in treating the psychotic child, have 
resulted in a paucity of controlled trials of lithium in this disorder.
The first publication of the effect of lithium in this condition in child­
hood, appeared by Van Krevelen in 1959. The publication described the
successful treatment of a fourteen year old boy who suffered from "periodic 
14 5
psychosis" ' . Eight years later Frommer reported on a group of nine­
teen children with ages ranging from five to fourteen years. Lithium 
therapy apparently benefiting the majority of the subjects ’ . The 
following year Annell reported on a group of twelve children and adolescents 
with ages ranging from ten to eighteen years. The symptom complex included 
a characteristic periodicity, but otherwise was quite variable.
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The serum lithium levels were maintained at levels from 0.6 to 1.2 m Eq/1.
Up to 1800 mg/d of lithium was required to sustain such levels. Eleven
of the twelve patients responded to lithium treatment. Those patients
who improved were diagnosed as having organic syndrome, periodic catatonia,
depression or anorexia nervosa. A great preponderance of periodic
14 f\
psychosis among their relatives was noted In 1970, Adams reported
a single case of a child who responded favourably to lithium ^ ' 7 . A 
survey of the literature by Youngerman in 1978 indicated that thirty of 
forty-five lithium-treated children with periodic mood swings benefiting
■r 4 - u  j  1 4 . 8
from the drug ‘.
14.1.3 Hyperactivity Syndrome
Seven hyperactive cnildren served as subjects in an uncontrolled trial
conducted by Whitehead in 1970. Lithium was administered with alternating
periods of placebo and thioridazine. Each period was four to twelve weeks,
Results indicated that the children were no less active on lithium compared
to placebo, and all children were less active on thioridazine, although not
to a marked degree. The author concluded that lithium had no appreciable
14 9
effect on hyperactivity ‘ . A double-blind, crossover study by Gram in 
1972 compared lithium with placebo in a group of eighteen young people.
Their ages ranged from eight to twenty-two years. All subjects viere 
psychotic with mixed diagnoses. All had evidence of psychosis prior 
to the age of five years. Raters were teachers and parents of the 
children. Nine children behaved better during the lithium period, one 
child improved on placebo, and eight demonstrated no difference between 
treatments. This improvement was noted particularly at school, in areas 
of disturbed activity, aggression, and depressed or elevated mood "^.10.
In 1973, Greenhill conducted a double-blind, controlled trial of lithium 
in nine children. The subjects were aged from nine to fourteen years, 
and all were grossly hyperactive. They were considered refractory to 
other treatment measures. Lithium or placebo or dextroamphetamine were 
employed in a crossover design. Results indicated that only two children 
improved on lithium. The improvement was only transient nature.
Both subjects also showed some affective features to their hyperactive 
behaviour 1^-11
105.
14.1.4 Monitoring Lithium in Children
1 4 4  14 \ 7
The renal lithium clearance is high in children ’ ’ '
14 13
therefore tolerate larger doses of the drug ’ .
Children 
The younger age group
is also less likely to suffer from serious side effects during lithium
treatment
14.5, 14.14
Cognitive side effects may be minimal
14.15
Before starting lithium the young person's physical health, their cardiac 
and renal function should be carefully checked. It may be of value to 
have also a baseline EEG and cognitive tests. In addition, thyroid 
function should be checked and if treatment continues for many months a 
growth chart should be maintained throughout treatment.
Salivary lithium estimates in children have been advocated as a substitute
14 16
for blood tests * . A correlation of serum and salivary lithium levels
has been postulated but this is disputed by Lena whose
findings indicate that salivary lithium levels in children are on average 
2j times greater than serum levels.
14.1.5 Conclusion
Despite a twenty-six year long usage of lithium in the younger age group,
insufficient knowledge regarding the use of this drug in the young is
available to establish a definite indication. Certain authorities consid
14 19
childhood a contra-indication to the use of lithium ’ . There appears
to be, however, a group of severely disturbed children who possibly could 
benefit from lithium therapy. These are children -
i) who display impulsive aggressive behaviour with an affective component.
ii) are unresponsive to other forms of treatment and
14 20
iii) where a strong genetic component exists * .
14.2 The Use of Lithium in the Elderly
The toxicity of lithium at elevated serum levels is well documented and the 
elderly patient certainly is not exempt from the same risks. On the con­
trary, literature suggests that the elderly may develop serious adverse effects
105.
at lower serum lithium levels. Shopsin in 1973 had already advised
14 21
against the use of lithium in these subjects ' . Several researchers
have documented neurotoxic manifestations in the elderly who were treated
14 22 14 23
with lithium, particularly in a combination with neuroleptics * ’ ' .
This neuro-toxicity occurred even at serum lithium levels within the
therapeutic range, and often presented in unusual forms, e.g. aphasia or
stuttering. In 1970, Baldessarini concluded that age was not correlated
14 24
with the appearance of lithium-induced CNS dysfunction ’ . A year later
Van der Velde advised lower lithium doses in the elderlv as this group might
14 25
respond to and require lower serum levels of the drug * . In 1972,
Prien reported that about five per cent of lithium-treated patients under
the age of sixty-five years could be expected to develop neurotoxic
. . , 14.26
symptomatology .
14.2.1 Lithiurn Trials in the Elderly
14.2.1.1
Himmelhoch in 1980, evaluated the course and treatment of eight-one
lithium-treated patients between the ages of fifty-five and eighty-eight
years. El event of fifteen patients with extrapyramidal symptoms developed
neurotoxicity at low serum lithium concentrations. The author postulated
that the neurological status, rather than age, was a determining factor in
14 27
the treatment with lithium ' .
14.2.1.2
In 1982, Smith compared the incidence of adverse effects of lithium 
between a group of patients aged sixty-five years and older, to a grouD 
of subjects younger than sixty-five years. The elder group was exposed 
to lower lithium dosages. Results indicated no significant difference 
between the groups with regard to overall incidence of adverse effects, 
but a statistically greater incidence of severe side effects was noted in the 
elder group. Of the latter group forty-three per cent showed signs and 
symptoms of lithium-induced neurotoxicity.
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It appeared that in both groups an increasing severity of adverse effects 
was associated with higher daily dosages of lithium. The author con­
cluded that the patient population over the age of sixty-five was parti­
cularly prone to develop side effects when treated with lithium even at 
therapeutic dosages .
14.2.1.3
In 1983, Murray studied 166 unipolar and bipolar outpatients ranging in age 
from twenty-one to seventy-eight years. The author could not demonstrate 
a general age-related decline in lithium efficacy. There was a tendency,
however, for the prevalence and severity of a fine hand tremor to increase 
with age .
14.2.2 Conclusion
In summary, it appears that the elderly are prone to develop, at therapeutic 
lithium levels, a neurotoxic syndrome which may surface in an unusual form.
108.
CHAPTER 15
Determination, Dosage and Preparation
15.1 Determination
Determination of serum lithium concentration is achieved by the method 
of flame emission photometry. This is a simple and inexpensive pro­
cedure, although not without disadvantages l5'1.
expensive method is by atomic absorption photometry.
15 ?
however, is considered less sensitive
A relatively more 
This procedure,
A few millilitres of fasting or non-fasting venous blood is collected
in a tube without anticoagulants. Haemolysis does not influence 
15 3
readings ‘ . This is surprising as the mean piasma-to-red blood
15 4
cell lithium ratio is approximately 3:1 ‘ . It is important that
the blood samples for lithium determination are drawn at a proper time 
in relation to the intake of lithium. Serum lithium concentration 
varies considerably throughout the day. During the absorptive peaks 
the level may rise one hundred per cent over the pre-absorptive level 
Standardization of a lithium estimation is therefore essential, and due
15.5
to the efforts of Grof and Amdisen, is set in the postabsorptive phase at
1 5 5
a ten to twelve hour interval following the last dose of lithium ‘ .
The use of saliva, and more recently of tears as a convenient alternative 
to the use of serum in determining lithium concentration has been advocated 
Research has, however, provided conflicting reports of the usefulness of
both
15.7, 15.8, 15.9
15.6
15.2 Dosage and Treatment
When considering a patient for treatment with lithium, the following may 
serve as contra-indications to the use of the drug :
1. Severe renal disease.
2. Severe cardiovascular disease.
109.
3. Pregnancy in the first trimester.
4. The unreliable and suicidal patient.
Relative contra-indications, where great caution in the use of lithium 
is indicated, are the following :
1. Mild to moderate renal disease.
2. Mild to moderate cardiac disease.
3. Organic Brain Syndrome.
4. Children and the elderly.
5. Breastfeeding.
6. Thyroid disease.
7. Concurrent diuretic therapy.
Before initiating treatment, a physical investigation with emphasis on the
15 4
thyroid status is imperative ‘ . Blood tests should include, at least, 
a serum sodium and potassium, a white cell count, and in children a serum
A r n
calcium Other laboratory tests might determine the urine osmolality.
15.4
A urinalysis and twenty-four hour creatine clearance may be helpful ,
An E C G in patients over forty years of age is advisable and if conditions 
permit, a baseline E E G .
Problems concerning dosage differ according to whether one is starting treat­
ment during a manic episode or using lithium as a maintenance treatment.
The size of the dose also depends on the severity of the illness, the 
patient's age, weight, physical condition, kidney function, and on whether 
the patient is receiving concomitant neuroleptics. Methods exist for 
the determination of the lithium dosage requirement before initiating treat­
ment. Schou had recommended creatinine and lithium clearance determinations 
for the prediction of maintenance dosage requirements. Cooper has 
described a technique whereby the individual dosage requirement can be
predicted from a single blood sample collected twenty-four hours after adminis-
15 11 15 12
tration of a 500 mg dose of non-sustained release lithium carbonate ‘ ‘ .
1513 1514 1515 1516
Several other researchers have furthered this techique * ‘ ’ ' ’ ‘
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and prediction tables have been compiled in order to calculate the 
lithium dosage required to attain a desired serum lithium level, e.g. :
24-h serum lithium level after From Cooper et al (1973)
single loading dose of 500 mg and Cooper et al (1976)
of standard lithium carbonate Daily lithium dosage required
( mg )
-CO,05 3000
0,05 - 0,09 2250
0,10 - 0,14 1500
0,15 - 0,19 1000
0,20 - 0,23 750
0,24 - 0,30 500
>0,30 400
15.2.1 Initial Treatment of Mania
When lithium treatment is started during mania, one may use lithium alone 
or administer it in combination with a neuroleptic drug. In the latter 
case, as occurs in the severely active manic patient, the neuroleptic func­
tions as a sedative and as an antip.sychotic. The dose of lithium and of 
the neuroleptic ought to be lowered when administered in combination.
When lithium is the only treatment, the initial dosage is usually double
15 2
that required for prophylaxis ’ . A dosage of about 1800 to 2500 mg/d
is advocated, and a serum lithium level not exceeding 2,0 m Eq/1 has been 
recommended ^.18^ Experience in South Africa, however, pleads in
favour of lower serum levels of 1 ithium^' Determinations of this
level are performed every two to three days to adjust the dosage in order to 
maintain the required level. Lithium therapy is continued for one to two 
weeks, or until the manic symptoms have disappeared. At this point the 
lithium requirement decreases and the dose of lithium should be reduced to 
maintain a serum level of 0,8 to 1,2 m Eq/1 ^.18^ Lithium is
continued as a maintenance treatment in the first attack for as long as 
the manic episode would have lasted had it remained untreated, usually 
one to two months, and is then discontinued.
In patients with frequent episodes, i.e. at least two clearly distinct episodes 
each lasting at least one month and within two years at most, the treatment
is often continued beyond the supposed end of the episode in order to 
prevent further relapses.
15.2.2 Maintenance treatment
Research has shown that most patients derive maximum benefit with a minimum
of adverse effects if the serum lithium concentration is between 0,6 to
1,1 m Eq/1. This level is usually achieved by 600 mg to 1800 mg lithium
daily ’ ’ . Serum lithium level estimations are
advisably performed weekly for one year after the manic symptoms have been
contained. Thereafter estimations are performed at two-monthly
intervals for the second year, followed by three-monthly intervals during
1521 15 ?3
the third year and the follow-up period ' ’ . Serum estimations
should be repeated more frequently than the advised schedule in the 
following conditions :
1 . one week after dosage changes;
2. patient on a salt-poor diet;
3. during slimming diets;
4. recurrent febrile illnesses;
5. imminent relapse;
6. diuretic therapy;
7. extra-renal sodium loss;
8. final trimester of pregnancy, especially the week 
prior to and following delivery.
15.3 Preparations
Two types of lithium preparations are manufactured: the ordinary and the 
sustained release or slow release types. In the latter the lithium salt 
is embedded in a matrix so that the active lithium salt is gradually released 
in the gastro-intestinal tract. This would lead to a diminished serum 
lithium blood peak, and should oppose the steepness of the peak-rise. 
Theoretically, these influences should result in fewer and lesser coincident 
adverse effects, thereby improving patient compliance
112.
Persson found that with a regular lithium carbonate preparation tremor
was related to higher gradients and peak levels, and nausea was related
to higher gradients ^5.25^ Repeated exposures to high serum lithium
levels as seen in the multiple daily dosage schedule may be more harmful
to the kidneys than the constant exposure to moderate lithium levels which
may result from the usage of the sustained action type of lithium prepara­
' 15.24
tion .
Some research has proven no diminution of these side-effects by some
1 5 2r i 5 "7
sustained-action lithium preparations ‘ ’ ’ . Studies
have also indicated that the citrate preparation may cause lower serum
15 28
lithium levels * . This should be a more useful preparation as
higher serum lithium peaks may be associated with a greater likelihood
15 12
of renal impairment ’ . The single daily dosage of the sustained-
action preparation, coupled with a decrease in adverse effects, may also 
encourage compliance which has been demonstrated to be lacking in a third 
of all 1ithiurn-treated patients ‘ . This figure has recently been
calculated to be as high as forty-four per cent
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CHAPTER 16 
PERSPECTIVE
This dissertation consists of a review of the literature, past and 
present, pertaining to the metal lithium. An overview is presented 
of its actions, its adverse effects and its uses in medicine, particu­
larly in psychiatry.
An enormous amount of literature on the psychiatric use of lithium has 
accumulated and is still expanding. Yet, like in most sciences, 
increasing knowledge leads to more unanswered questions. The
mechanism of lithium's action is unestablished. A number of cellular 
processes are known to be influenced by the drug, but which of these 
could be responsible for its action is unknown. One may presume 
a single basis for its action as unlikely.
Treatment with lithium is by no means innocuous. This aspect is borne 
out by its numerous side effects and its narrow therapeutic range.
This has presumably caused many practitioners to forego or delay treat­
ment in the face of urgent indications for its legitimate and rightful 
usage. But in which direction (s) might one ask lies the value of 
this salt? The many open and uncontrolled trials of lithium in mania 
show a remarkable degree of consistency in concluding that the drug has 
definite therapeutic properties in eighty per cent of manic patients.
Lithium has a specific effect against pure mania without sedation, seen 
with phenothiazines. This antimanic effect, however, is produced more 
slowly than the phenothiazines, and accounts for the lag period of up to 
a fortnight. Despite this, the drug still remains the treatment of 
choice in this disorder. Combining other treatments with lithium is 
fruitful in the lithium-resistant manic patient. The case in favour 
of prophylactic lithium is sufficiently impressive to justify its use as 
maintenance treatment in bipolar disorder. In dysthymic conditions 
and in severe unipolar states lithium appears without any established value.
Its antidepressant effect on the moderate to mild unipolar state is at 
most a weak one. Yet in patients refractory to standard methods of 
antidepressants it may be usefully added to the existing treatment.
Data suggest that in schizophrenia the neuroleptics remain the treatment 
of choice. Schizoaffective patients, particularly those displaying 
activity and affective components to their illness benefit more from
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lithium than from neuroleptics. When the drug has been administered in 
other disorders, ranging from anorexia nervosa and bulimia, through 
personality dysfunctions to transvestism, it appears that only the affective 
overlay is influenced by the drug. Lithium, however, seems more effective 
in certain aggressive states, particularly when the aggression is coupled 
to restlessness and mental retardation. But the exact limits of its 
usefulness in aggression have yet to be defined.
Used indiscreetly, lithium can be injurious. Utilized suitably and 
with foresight, it can radically change the lives of patients, who, until 
the inception of lithium treatment were burdened with frequent and severe 
manic and depressive episodes. It should be realised that once the 
simple pharmacokinetics of the treatment are comprehended, it should be 
possible to harness a therapeutic system which is sure and effective, and 
which demands less time, energy and expenditure from the patient and his 
psychiatrist.
No other drug has come close to stirring up the kind of international 
controversy that has been generated by this simple salt of an alkali metal.
For the first time in the history of psychiatry a naturally occurring salt 
controls a major affective disorder. Such an extra-ordinary claim for 
any psychiatric drug, has widespread consequences. To begin with, the 
correct treatment of affective disorders requires some psychiatrists to change 
their conceptual framework of these conditions. Secondly, conclusive findings 
would strengthen the hypothesis of a genetically inherited biochemical defect(s) 
in the major affective disorders that might in some ways be corrected by this 
ion. One cannot help waxing emotional over these possibilities. Thus, it 
comes as no surprise that those who have claimed lithium to be a panacea, but 
have failed to produce sound statistical evidence to support their claims would 
be fiercely attacked by clinicians who have seen wonder drugs surface only to 
soon founder. To be sure, this emotionally heated debate surrounding lithium, 
ought to make one sceptical in evaluating negative as well as positive claims.
"Is not a mystery of nature 
concealed even in poison?
Why then should poison be rejected
and despised, if we consider not
the poison but its curative virtue?"
Paracelsus 1493 1541
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